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MECHANISMS MEDIATED BY CXCL 12 SIGNALING THROUGH 
CXCR4 AND CXCR7 IN BREAST CANCER 
LaSharon D. Mosley 
DECEMBER 2009 
Interactions between chemokines and their receptors are involved in organ-
specific homing and propagation of metastatic breast cancer (BrCa) cells. BrCa 
cells express higher levels of CXCR4 and CXCR7 mRNA and cell surface 
protein, than normal human mammary epithelial cells (HMECs). CXCR4 is 
ubiquitously expressed by a multitude of cancerous and normal cell types; while 
CXCR7 is differentially expressed by T helper lymphocytes, cancer cells, and 
normal epithelium. Importantly, recent studies show CXCR7 is highly expressed 
by activated endothelial cells (Le., neovasculature), fetal liver cells, and many 
tumors, but not by non-transformed (or normal) human tissues. Unlike other 
chemokine receptors, activation of CXCR7 does not cause Ca2+ mobilization/flux 
or cell migration. However, CXCR7 activation by its ligands (CXCL 12 or 
CXCL 11) provides signals for growth, survival, and adhesion. Preliminary 
studies demonstrated CXCR7 expression is significantly higher in BrCa cases 
than compared to non-neoplastic tissues. Further, CXCR7 mRNAs are elevated 
in the BrCa cell line MCF-7, with modest expression in MDA-MB-231 when 
v 
compared to HMEC. Other studies revealed cell-type specific expression of 
CXCR7 may modulate BrCa progression. Together, these findings provided the 
rationale to support the hypothesis that CXCR7 and its interactions with CXCR4 
and CXCL 12 promote arCa cell collagenase expression, alter NF-KB and 
ERK11210calization to the nucleus, and correlates with cell cycle. Two Specific 
Aims were used to test this hypothesis. Aim 1 - Determined the differential and 
cell cycle-dependent expression of CXCR7, CXCR4, CXCL 12, matrix 
metalloproteinase proteins MMP-1 and/or -13 in BrCa cells, which were affected 
by CXCL 12 stimulation. Aim 2- Characterize some of the CXCL 12-dependent 
mechanisms involved in BrCa progression. 
The results from this study indicate that differential and cell cycle-
dependent CXCR7 and CXCR4 expression plays a critical role in enhancing 
BrCa cell invasion and survival cell signals, which were CXCL 12-dependent but 
often G protein independent. Further, CXCL 12-induced CXCR4 mRNA 
expression required G~y protein and/or JAKISTAT signal transduction. It was 
also shown that CXCL 12-mediated CXCR7 mRNA expression in a pertussis 
toxin sensitive and no doubt required Gai protein signaling. In confirmation with 
previous studies from Wendt et aI., CXCL 12 expression is negatively regulated 
by the presence of CXCR4. Lastly, CXCL 12-dependent MMP-1 and MMP-13 
mRNA expression is Ga protein-, G~ protein-, and Gy protein-dependent 
presumably through CXCR4, while elevated expression of CXCR7 suppresses 
these effects. 
VI 
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Metastasis is a non-random and specific process that includes: survival 
and growth of the primary tumor, detachment of tumor cells from the primary site, 
invasion into the vascular or lymphatic vessels, homing and adherence to the 
secondary site, survival, growth and angiogenesis of the metastasized cells at 
the secondary site (1). This process is responsible for all breast cancer (BrCa)-
related deaths; therefore, therapies designed to prevent the spread of BrCa cells 
are greatly needed. The current theory for malignant cancer is that metastasis is 
the final stage of disease (2). Most importantly, cancer cells involved in the 
progression of the disease have acquired the necessary hallmarks of malignancy 
as they accumulate multiple, rate-limiting mutations that occur over an extended 
period of time. The primary idea behind early cancer detection and prevention 
strategies is that carcinogenesis can be suppressed during the post-initiation 
stage of disease, specifically due to cancer's progressive nature and long latency 
(3). However, the current concept of cancer is that disease progression is a 
mUlti-step process that arises late from rare transformed cells with metastatic 
potential (4, 5). For example, histological studies of epithelial cancers showed 
progression of the disease from benign through malignant stages. Further, 
metastatic tumor cells must be able to colonize at distant organs (6). 
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BrCa is the second leading cause of cancer-related deaths among women in 
the US. Similarly, the numerous anti-apoptotic mechanisms employed by BrCa 
cells to survive, serum-free environments or apoptosis-inducing therapies 
significantly contributes to the morbidity and mortality of this disease. Its 
progression consists of atypical ductal hyperplasia, pre-invasive ductal 
carcinoma in situ (DCIS), and invasive ductal carcinoma; however, the 
mechanisms responsible for BrCa metastasis and resistance to therapy are 
incompletely understood. Many factors have been implicated in the process of 
metastasis, serum-free survival and resistance to therapy, but the precise 
mechanisms are not entirely known. Brugge et al. demonstrated that a 
combination of oncogenes, one for constitutive proliferation along with another 
that inhibits apoptosis, are required for metastatic progression (7). Other studies 
have implicated physiological changes in the stroma or microenvironment maybe 
key to tumor progression or phenotypic reversion. Indeed, disrupting tumor cell 
interaction with the extracellular matrix (ECM) via integrin blocking antibodies 
resulted in a phenotypic reversion (8). Other observations in prostate and breast 
cancer models demonstrated that normal stromal fibroblasts are replaced by 
smooth muscle reactive myofibroblasts or carcinoma-associated fibroblasts to 
promote disease (CAFs). These CAF cells alter ECM composition, elevate 
cytokine production, and induce the infiltration of inflammatory cells (9, 10). 
Along this line, the pro-tumorigenic functions of CAFs in mammary carcinomas 
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are partially mediated by CXCL 12, is expressed at increased levels by mammary 
carcinoma CAFs and it plays a critical role in disease progression (11). 
CXCL 12 directly stimulates tumor growth by binding to and signaling through 
CXCR4 on tumor cells. This chemokine also recruits ECs into tumors by 
facilitating angiogenesis (12). Local injury, inflammation, and/or tumor cells (via 
paracrine signaling to stromal cells) are able to induce a microenvironment that is 
conducive for tumor cell progression. These studies also demonstrate that 
pathological changes in the tumor microenvironment maybe just as important for 
BrCa progression as mutational-oncogenic profiles of the tumor cell. Given the 
importance of stromal-epithelial interactions in normal mammary gland 
development, tissue homeostasis, and tumor progression, chemokines and their 
receptors play critical roles in each process (13). The goal of this dissertation is 
to determine or gain a better understanding of chemokine ligand CXCL 12 and its 
receptors, CXCR4 and CXCR7, interactions. 
Chemokines 
Chemokines are 8-10 kDa chemotactic cytokines that are classified into four 
groups (CXC, CC, C, and CX3C) based on the position of the first two cysteines 
(14). Chemokines bind receptors that belong to the G protein-coupled receptor 
superfamily often coupled to pertussis toxin sensitive Gi proteins (15) (Figure 1). 
In general, chemokine receptors exhibit promiscuity, being able to bind multiple 
ligands; however, 6 of the 18 chemokine receptors bind a single ligand (16). In 
recent years, chemokines and their receptors have been implicated in several 
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Figure 1. Previously shown CXCR4 cell-signaling pathways. The GPCR, 
CXCR4 binding of SDF-1 has been shown to activate G-proteins (heterotrimer 
aJ~/y) mediated signaling to elevate intracellular Ca2+(Calcium) , activate MAPK 
(Mitogen Activated Protein Kinases) , JNK (Jun N-terminal Kinases) and PI3K 
(Phosphoinositide-3 Kinase) . Cell signaling through these pathways lead to cell 
growth , migration and polarization. CXCR4 stimulation by SDF-1 also results in 
increased phosphorylation of focal adhesion components e.g. the related 
adhesion focal tyrosine kinase (RAFTKlPYK2) , Crk and Paxillin . Crk, which 
belongs to the adaptor family of proteins composed of SH2 (Src Homology 2) 
and SH3 domains, has a putative role in signaling. The phosphorylation and 
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translocation of NF-kB, c-jun/c-fos, and ERK1/2 are also critical for activating 
genes and transcriptional factors involved in many cellular events including: 
tumorigenesis, differentation, migration, growth and survival. JNK, which is 
moderately activated by v-Crk as well as Rac and Cdc42 (Cell Division Cycle 42), 
can activate genes needed for cell proliferation and survival. All of these 
signaling pathways are key for the role of CXCR4 in BrCa progression. 
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diseases, including cancer. They are secreted cytokine-like proteins that induce 
the direction of metastasis and survival of neoplastic cells through G-protein-
coupled receptors, cytoskeleton rearrangement and adhesion of neoplastic cells 
to leukocytes and endothelial cells (14,17,18). These secreted factors act in a 
coordinated fashion with cell-surface proteins to direct the homing of various 
subsets of haematopoietic cells to specific organ sites (19). Studies have shown 
that secondary sites of BrCa metastasis, e.g., lung, liver, and bone are abundant 
sources of these ligands (19). Studies within our laboratory and others (Table 1) 
have shown chemokine involvement in cancer development and progression, 
including metastasis. This association with metastasis is not unusual since it is 
not a random process of cell migration. Metastasis has many features in 
common with normal cell migration; however, key differences lie in abnormal 
chemokine receptor expression, regulation or use (20). The role of chemokines 
and their receptors with regard to cancer has been divided into three broad 
categories. First, they must provide directional cues for tumor cells to migrate or 
metastasize at secondary sites. Second, they can favorably shape the tumor 
microenvironment for the "metastasized" cells. Third, they provide survival and 
growth signals for cancer cells (21,22). Although chemokines and their 
receptors' involvement in each of these categories has been well established, 
their exact mechanism of action are not well understood and the underlying 
complexity of chemokine networks makes it difficult to characterize them 
definitively. However, CXCL 12 and its receptor CXCR4 have been implicated in 
23 different types of cancers (23). 
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Chemokine Receptor Chemokine Ligand (s) Disease Investigated & 
Pub 
CXCR3 CXCl9, 10, & 11 Cystitis, 2008 & 2003 
CCR5 CCl5 Chlamydia, 2008 
CXCR3 CXCl 10 & 11 Colitis, 2008 
CXCR3 CXCl9, 10, & 11 IRB, 2007 
CCR5 CCl3, 4 & 5 Pneumonia, 2006 
CCR1, 3, & 5 RANTES Malaria, 2005 
CCR9 CCl25 Prostate Cancer, 2004 
CCR3,8 1-309, vMIP-11, & TCA-3 Mucosal Immunity, 2004 & 
2001 
CXCR4 CXCl12 Prostate Cancer, 2004 
CXCR5 CXCl13 Prostate Cancer, 2008 
CXCR1 and 2, Il-8R~ GCP-2 & Il-8 Adaptive Immunity, 2004 
&2003 
CCR1 RANTES Mucosal Immunity, 2001 
Table 1. Chemokines and Disease: Chemokine ligands and their receptors CBxpression in various diseases. 
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Human Stromal Cell-Derived Factor-1 , also known as CXCL 12, has two 
known isoforms (SDF-1 a (89 aa) and SDF-1 ~ (93 aa)) that binds the 352 aa 
rhodopsin-like GPCR, CXCR4 with comparable affinity (Kd of 7.5 and 13.7nM 
respectively) (24, 25). The CXCL 12/CXCR4 axis is one of the best studied, 
primarily due to their roles in HIV entry (26) as well as their ability to mediate the 
metastasis of a variety of cancers (27). Studies have shown that CXCL 12 affects 
growth and spread of cancer cells through interactions with CXCR4 (19). 
CXCR4 has been shown to playa major role in the progression of multiple types 
of carcinomas and this chemokine receptor is widely expressed by astrocytes, 
glial cells, and neurons of the adult nervous system as well as normal epithelial 
cells. Of particular interest, CXCR4 is constitutively expressed by cortical and 
hippocampal neurons as well as epidermal cells. 
Other factors have also been shown to enhance CXCR4 expression 
specifically during cancer progression. Further, CXCR4 is expressed by many 
cancer cells, cell lines and endothelial cells around tumor lesions (28). Other 
studies have shown that CXCR4 may influence migration in the peritoneum, a 
major route for BrCa cell spread to lymph nodes (19, 29). Increased cell surface 
expression of CXCR4 maybe the result of altered regulation, independent of 
effects on transcription or translation. Ubiquiination of CXCR4 is a post-
translational modification regulating the expression of this receptor (30). 
Interestingly, BrCa cells that are HER2/neu positive have increased expression 
of CXCR4 as a result of reduced CXCR4 ubiquitination. This provides a potential 
link between HER2 positive BrCa and the attenuated degradation of CXCR4 
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(31). To this end, neutralizing CXCR4 significantly impaired BrCa cell metastasis 
to regional lymph nodes and lung (19). 
Several clinical studies have noted that the progression of BrCa and tumor 
burden correlates with inflammatory and acute phase protein levels in sera. For 
example, patients with metastatic BrCa express significantly more serum IL-1~, 
IL-6, and TNF-a when compared to healthy donors or patients without neoplasms 
or with benign or localized breast tumor (32). Stimulation of fibroblast or 
endothelial cells with IL-1~, IL-6, and TNF-a, which are elevated during BrCa 
burden, results in the production of several factors including CXCL 12 (33) and 
CXCL 11 (34). Elevation of these factors often correlates with poorer disease 
outcomes, tumor size, and metastasis. To explain, the bone marrow responds to 
infection (and tumor burden) by producing more mature leukocytes from a small 
pool of committed progenitor cells under the influence of colony-stimulating 
factors (CSF) (35). Similarly, factors produced during this innate response are 
involved in the expression of chemokines and cell adhesion molecules by human 
bone marrow endothelial (HMBE) cells and osteoblasts (36, 37). Of importance, 
osteoblasts have been demonstrated to express and respond to CXCL 12 (38). 
Mutation of CXCL 12 leads to a defect in the guided migration of the lateral 
line of zebrafish. This defect caused by CXCL 12 mutation is surprisingly 
stronger than those caused by CXCR4 deficiency (39). Perhaps tumor cell 
invasion, like tissue development, is a collective phenotype of several signals 
and cells. Perhaps, extrinsic cues and interactions influence a small number of 
"leader" as well as "trailing" cells. Recent studies have shown that CXCR4 is 
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required at the leading edge, while another chemokine receptor that also binds 
CXCL 12, CXCR7, is expressed by trailing regions to presumably support 
migration, differentiation, and/or adhesion (i.e., arrest). Knockdown of CXCR7 
affected trailing cells and caused stretching and incomplete or "stalled" tissue 
formation in zebrafish (40, 41). Other studies demonstrated that CXCR4 and 
CXCR7 act independently to regulate cell migration and this relationship is 
believed to be synergistic; however, activation of both receptors is controlled 
directly by CXCL 12 (34). While there are several mechanisms that are common 
among tissue development or wound healing and tumor metastasis, further 
studies are required to determine how this elegant interaction between CXCR7 
(CXCL 11 and CXCL 12) and CXCR4 (CXCL 12) may determine breast tumor 
development. My dissertation addressed and dissected some of these cellular 
and molecular mechanisms. 
CXCR7 
My preliminary histological studies show that BrCa tissue also express 
higher levels of CXCR7 (Figure 3) to presumably dictate cell adhesion, invasion 
and survival in response to chemokine ligand CXCL 12. CXCR7, formerly called 
RDC1, is a recently de-orphanized G-protein coupled receptor that binds with 
high affinity to two chemokines - CXCL 11 (interferon-inducible T cell 
chemoattractant; I-TAC) and CXCL 12 (stromal cell-derived factor-1; SDF-1). 
Receptor-binding studies revealed that CXCL 12 has a higher binding affinity for 
CXCR7 than compared to CXCL 11 (~3-fold more efficiency) (34). Originally, 
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cloned from a canine cDNA library as a putative G-protein coupled receptor for 
vasoactive intestinal peptide hormone (VIP), a connection between RDC1 and 
chemokines was proposed based on sequence similarity (43%) and identity 
(32%) with CXCR2, CXCR1 and CXCR4 on human chromosome 2. Despite its 
phylogenetic relation and ligand-binding properties, CXCR7 has not yet found 
general consent as a typical chemokine receptor (42). For example, chemokine 
receptors often signal via pertussis toxin sensitive Gai-proteins and contain a 
conserved DRYLAIV motif at the N-terminus of the second intracellular loop that 
is sufficient for coupling to Gai-proteins. CXCR7 coupling to G-proteins has not 
been demonstrated and it has an altered DRYLSIT motif, which may disallow it to 
optimally interaction with these signal transducing proteins (42). Most 
importantly, the third intracellular loop, which is generally less conserved 
between GPCRs, confers specificity for G-protein interactions (Figure 2), but the 
function of this site remains in question, because CXCR7 activation is atypical 
when compared to signals induced by other CXC chemokine receptors (43). 
Activation of CXCR7, whether by CXCL 11 or CXCL 12, does not cause 
Ca2+ mobilization or cell migration; however, expression of CXCR7 provides cells 
with increased growth and survival properties (44). In studies involving CXCR4+ 
HEK293 cells, expression of CXCR7 showed enhanced cell responsiveness to 
CXCL 12 (44). Other studies showed CXCR7 is critical for CXCL 12 mediated 
survival, tumor growth and aggressiveness (42). Due to these studies, it could 
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Figure 2. Hypothetical CXCR7 (G protein-independent) cell-signaling 
pathways. The GPCR, CXCR7 is hypothesized to signal via a pathway 
independent of its G-proteins (heterotrimer subunit apy) but involves crosstalk 
with CXCR4. Interaction with JAKISTAT with the C-terminal tail of the receptor is 
key for the activation of PI3K that induces downstream cascade components 
MAPK, AKT, Rho GTPases, and Rho Gefs. These signaling pathways for 
CXCR7 enhances protein translation , cell adhesion , migration, and survival in 
BrCa. 
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Although CXCR4 was once believed to be a receptor unique for CXCL 12, 
my preliminary studies and those of others suggest that CXCR7 acts either as a 
"scavenger receptor" with limited function or a receptor that amplifies or fine-
tunes CXCL 12 cues for cell migration, adhesion, invasion and/or survival. When 
both CXCR4 and CXCR7 are expressed, studies show that these chemokine 
receptors efficiently form heterodimers, which could have consequences on 
CXCL 12-mediated signals (45). Moreover, the relative CXCR4 or CXCR7 
expression levels contribute to the occurrence of these heterodimers. Using 
bioluminescence resonance energy transfer (BRET) analyses, Levoye et a/. 
demonstrated that CXCR7 expression alters CXCR4-mediated Gai protein 
complexes and impaired CXCR4-promoted Gai protein activation and Ca2+ 
responses. In the same study, RNA interference targeting CXCR7 and blockade 
of CXCL 12/CXCR7 interactions contributed to reduced chemotaxis toward 
CXCL 12 in primary T cells. This study along with others, identified 
CXCR4/CXCR7 heterodimers as distinct functional units with novel properties 
that can contribute to the activity of CXCL 12. Lastly, no cellular signaling 
pathway(s) , e.g., extracellular signal-related kinase (ERK1/2), AktlPKB, 
phosphoinositide 3-kinase (PI3K), and Src, have been determined for CXCR7. 
Studies within this dissertation will help to elucidate some of these events. 
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Chemokine-Induced Integrin Activation and Firm Adhesion 
Primary leukocyte adhesion to endothelium, namely, tethering and rolling, 
are mediated by chemokines as well as integrins. Transendothelial lymphocyte 
motility during inflammation is a complex process that involves cell rolling along 
the endothelium of extracellular matrixes (ECM). This rolling continues until a 
high concentration of a given chemokine is detected which results in integrin-
dependent firm adhesion and cell arrest at the site of secretion. Hence, 
chemokines aggregate not only their respective receptors but also bring together 
and activate integrins to increase the binding avidity for firm cell adherence that 
can resist the shear force exerted by blood flow (46). Several chemokines have 
been shown to modulate lymphocyte adhesion to endothelium or endothelial 
ligands (47-51). Elucidating the mechanisms of integrin activation by 
chemokines at confined leukocyte-endothelium contact zones under shear flow 
is crucial for understanding how chemokines regulate BrCa cell metastasis. 
Chemokine-triggered G-protein signaling coupled to integrin clustering takes 
place within sub-seconds. Endothelium expressed chemokines, e.g., CXCL 11 
and CXCL 12, might function to augment BrCa cell arrest under physiological flow 
conditions. 
Cytoskeleton re-modeling, adhesion and de-adhesion are not only required 
for cellular motility, but are also linked to proliferation and survival pathways. 
Integrins elicit a series of transduction signals (e.g., focal adhesion kinase (FAK), 
Src, ERK1/2, mitogen-activated protein kinase (MAPK), PI3K, etc.) that influence 
cell proliferation and survival (52, 53). While a6~1 has a high affinity for 
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fibronectin, av~3 adhesion depends on vitronectin and osteopontin constituents in 
bone ECM (37). Uv~3 and Uv~1 integrin expression by breast tumors correlates 
with poor prognosis and promotes BrCa cell survival and proliferation under 
adverse conditions (54-57). G-protein coupled receptor activation has been 
shown to induce ~3 integrin tyrosine phosphorylation via Src (58). Activation 
(phosphorylation) of the ~3 integrin subunit has also been shown to augment the 
interaction with its substrate for tight binding and signaling events (59). 
Matrix metal/oproteinase (MMP) and cancer progression 
Activation of CXCR4 stimulates the production of MMPs (60) potentially 
facilitating the ability of cancer cells to egress from the primary tumor site and 
invade secondary sites. Furthermore, CXCL 12 signaling is able to enhance 
integrin activity through cell adhesion under flow conditions (17, 61). Upon 
entering the blood or lymphatic systems, if CXCR4 truly mediates metastasis, 
tumors would preferentially migrate and adhere to areas that highly express 
CXCL 12. BrCa cells follow this distinct pattern of metastasis to lymph nodes, 
lung, liver, and bone marrow all of which express high levels of CXCL 12. av~3 
expression by MDA-MB-231 cells promotes bone tumor burden and 
destruction/invasion (62), in part through MMP upregulation (63). 
After adhesion, neoplastic cells must penetrate the basement membrane 
and invade the interstitial stroma to initiate the metastatic process. Many 
proteinases are capable of degrading ECM components, but MMPs (e.g., 
collagenases, gelatinases, and stromelysins) appear to be particularly important 
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for matrix degradation (64, 65) and cancer cell dissemination (66). Several 
MMPs and tissue inhibitors of MMPs (TIMPs) are highly expressed by invasive 
BrCa cell lines (MDA-MB-231) as well as breast tumor tissue. MDA-MB-231 
cells express and secrete active MMP-1, -3, -7, -9, -10, -11, and -13, whereas 
MMP-9 is specifically up-regulated by cell contact (67, 68). Indeed, expression of 
CXCR4 and MMP-9 by breast tumors correlates with a poor diagnosis of lymph 
node metastasis (69). Consistent with their role in BrCa progression, high levels 
of at least MMP-2, -9, -11, and -14 have been found to correlate with poor 
prognosis of patients with BrCa (70, 71). Accordingly, inhibitors of 
CXCR4/CXCR7 or siRNA knockdown inhibit metastasis and growth of breast 
cancer cells (72, 73). Our laboratory has previously shown that CXCL 12 can 
modulate the expression of collagenase, gelatinase, and stromelysin to support 
cancer cell invasion (74). To this end, studies attempting to correlate mestastatic 
potential and MMP involvement have yielded mixed results. This dissertation 
investigated the effects of CXCL 12 interactions with CXCR7 and CXCR4 that 
support active collagenase (MMP-1 and MMP-13) expression. 
Chemokine Receptor Signaling 
It has become evident that integrations between chemokines and their 
receptors lead to signal transduction that requires cell-cell adhesion molecules, 
cell-matrix receptors, and intracellular signaling proteins. A number of kinases 
have been shown to playa role in leukocyte (as well as cancer cell) adhesion, 
motility and invasion. Chemokine-induced integrin clustering and affinity 
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upregulation as well as chemotaxis by lymphocytes via F-actin polymerization 
and lame IIi-podia formation depends on a signaling network involving Rac, 
Cdc42 and Rap (75-78). Indeed, different signal transduction proteins may 
regulate multiple invasion events, including adhesion, de-adhesion, motility, and 
invasion using pathways such as the Src-ERK, FAKlPYK2-ERK, PI3K-Akt-NF-
1(B, and/or DOCK2-ELMO for Rac and/or Rap activation cascade(s). The current 
dogma for chemokine receptor signaling involves Gai protein, PI3K (upstream of 
ERK1/2), and phospholipase C (PLC) activation that leads to Ca2+ flux required 
for Src and FAK activation. There is no doubt that PI3K is a key signaling 
molecule that is activated after chemokine-chemokine receptor interactions by 
BrCa cells. Certain isoforms of p11 0 act to catalyze the formation of PI (3,4,5) 
P3 and subsequent production of PI (4,5) P2 by PTEN or PI (3,4) P2 by SHIP, 
which leads to the activation of Akt(s) (subsequent activation of NF-1(B) and 
ERK(s) to regulate cell functions including: proliferation, survival, membrane 
trafficking and cytoskeletal structures (79). 
Src activity is involved in cell invasion (and possibly motility) through its 
central role in the scaffolding complex of signaling molecules at the focal 
adhesion signaling organelle (80). Activation by auto-phosphorylation of FAK 
induces another pathway for motility and/or invasion (80-82). PI3K(s), Src, and 
FAKlPYK2 can also activate ERK(s) for migration, adhesion and invasion (81, 
83-86). It has been suggested that integrin avidity modulation by leukocytes 
appears to be mediated by ERK1/2. 
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Akt binds to the phospholipids produced by PI3K and recruits this kinase to 
the plasma membrane, where it is activated by phosphorylation. The non-
universal role of PI3K in BrCa cell motility, adhesion, and invasion has important 
implications for the development of new targets against metastatic cancers. 
Leukocyte migration seems to be mediated in a predominately Pl3K-independent 
and DOCK2-dependent manner (87). While PI3K and (Src and FAK) events 
have been shown to playa role in cancer cell motility, adhesion, invasion, and 
survival (88, 89), the potential of Pl3K-independent in CXCR7-mediated events 
remain uncertain. Most likely, Pl3K-dependent and -independent pathways may 
be involved in CXCR7-triggered integrin activation, for subsequent adhesion and 
invasion. 
Chemokine Receptors and Cell Survival 
The expression of chemokine receptors on migrating cells may provide 
these cells with more than directional cues for metastasis. Chemokine receptor 
signaling may provide a survival advantage once in a foreign environment. 
These molecular strategies for survival and growth are often the result of using or 
reprogramming existing physiological pathways (90). In most cases, survival 
signals are likely related to the role of chemokine receptor pairs e.g., 
CXCL 12:CXCR4 and CXCL 12:CXCR7 in normal development. Other situations 
for cell survival and proliferation may require redirecting signals from existing 
migration pathways. For example, studies have shown that metastasized cancer 
cells have a strong propensity to survive and resist apoptotic stimuli and in some 
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cases, extracellular survival signals can aide or promote cell survival in the 
"foreign" microenvironment (91). 
Unlike other chemokine receptors (e.g., CXCR3 and CXCR4), CXCR7 
does not induce Ca2+ flux or migration by BrCa cells (44). However, CXCR7 
promotes cell survival and adhesion (92). Studies have also shown that 
chemokine receptor signaling often leads to activation of Akt and subsequent 
phosphorylation of multiple targets, e.g., glycogen synthase kinase (GSK)-3~, 
Forkhead [Drosophila] homolog 1 [rhabdomyosarcoma] (FKHR) and caspase 9 
(without caspase 3 induction), which are involved in cell survival (93). The 
current dogma for chemokine receptor signaling involves Gai protein, PI3K, and 
PLC activation that leads to Ca2+ flux. There is no doubt that PI3K can be a key 
signal after CXCR4 and CXCR3 activation on BrCa cells. The prosurvival 
molecule Akt binds to the phospholipids produced by PI3K through its PH domain 
and is recruited to the plasma membrane where it is activated by 
phosphorylation. Phosphorylated Akt in turn phosphorylates Bad, a pro-apoptotic 
protein belonging to the BcI-2 family. When phosphorylated, the cytoplasmic 
protein 14-3-3 sequesters Bad and apoptosis is inhibited. 
A second Akt substrate includes FKHR (94-96). Phosphorylation of FKHR 
prevents translocation of this protein to the nucleus where it regulates the 
transcription of genes involved in apoptosis (97). ERK1/2 signaling may also 
contribute to cell survival through these pathways. For example, studies have 
shown that ERK1/2 via phosphorylation and inhibition of procaspase-9 and BAD 
may provide signals for cell survival and proliferation (98). Further studies 
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showed ERK1/2 can localize to the nucleus and activate transcription factors 
involved in cell-cycle regulation and differentiation that promotes cell proliferation 
(99). Thus, chemokine receptor signaling can activate transcription factors 
involved in anti-apoptotic mechanisms, cell-cycle regulation, and growth-factor 
production. These pro-tumorigenic pathways are likely to be particularly 
important for the ability of metastatic cancer cells to thrive in foreign 
microenvironments. These studies provide the rationale for my dissertation, 
which has demonstrated some of the mechanisms of CXCR7 and CXCL 12 
interactions and subsequent signaling events that promote BrCa cell invasion 
and su rvival. 
Apoptosis 
Apoptosis is an intrinsic cellular defense mechanism against tumorigenic 
growth, which, if suppressed, can contribute to development of malignancy (100). 
A wide variety of cytotoxic agents with different intracellular targets can induce 
the uniform phenotype of apoptosis (100). This implies that the cytotoxic activity 
of anti-cancer drugs is not solely dependent on specific drug-target interaction, 
but also on the activity of apoptotic (cell signaling) machinery of the cancer cell 
(101, 102). There are numerous downstream effectors and transcription factors 
of Akt, ERK1/2, and tyrosine kinase signaling that can promote cell survival and 
proliferation. Chemokine signaling often activates NF-KB, which is commonly 
downstream of Akt, but can be activated through other pathways, such as PKC 
(103). NF-KB dimerizes and translocates to the nucleus of the cell upon 
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activation where it promotes transcription of various apoptosis inhibitors and cell 
cycle-promoting genes (104). Interestingly, other downstream cell signaling 
targets through select chemokine receptors activate AKT - NF-KB to promote the 
phosphorylation of procaspase-9 and BAD, which inhibit cell signals that dictate 
apoptosis (105). Together, these studies support the notion that CXCR7 (and/or 
CXCR4) signaling can interfere with apoptosis signals induced by serum 
starvation. Therefore, I hypothesized that CXCR7 and its interactions with 
CXCR4 and CXCL 12 promote BrCa cell collagenase expression, alter NF-KB 
and ERK1I2 localization to the nucleus, and correlates with cell cycle. This 
hypothesis was investigated by immunohistochemistry, semi-quantitative RT-
PCR, siRNA, Activity Assays, and Amnis ImageStream analyses. These 
methods were sufficient for determining CXCR7 mRNA and protein levels in 
BrCa cells. By varying CXCR7 expression with siRNA and inhibitors (pertussis 
toxin (Gai) and U-73122 (G~/Gy), I have determined some of the cell signal 
pathways induced by CXCR4 and CXCR7. 
The Specific Aims of my dissertation focused on correlating CXCR4 and 
CXCR7 expression by BrCa cells with cell cycle, collagenase expression, as well 
as chemokine receptor, NF-kB, and ERK1/2 localization. The results obtained 
from this study will extend our knowledge concerning CXCR7 and its role in 
breast cancer progression as well as determine whether or not therapeutic 
targeting of CXCR4 and/or CXCR7 can alleviate BrCa cell invasion and survival. 
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Overall Hypothesis: CXCR7 and its interactions with CXCR4 and CXCL 12 
promote BrCa cell collagenase expression, alter NF-KB and ERK1/2/ocalization 
to the nucleus, and correlates with cell cycle. 
Specific Aim 1: Determined the differential and cell cycle-dependent expression 
of CXCR7, CXCR4, CXCL 12, and collagenase by BrCa cells, which were 
affected by CXCL 12 stimulation .. 
Specific Aim 2: Characterized some of the CXCL 12-dependent mechanisms 




MATERIALS AND METHODS 
Human BrCa cell lines, MCF-7 (HTB-22) and MDA-MB-231 (HTB-26), 
were purchased from American Type Cell Culture. Primary human mammary 
epithelial cells (HMEC) were obtained from LONZA. HMEC, MCF-7, and MDA-
MB-231 cell lines were used for all experiments performed and discussed. 
HMEC were maintained in MEGM supplemented with 2ml of BPE, 2ml of 
hydrocortisone, 2 ml of human epithelial growth factor (hEGF), 500 I of insulin, 
and 2 ml of gentamicin/amphotericin-B. MCF-7 and MDA-MB-231 cells were 
maintained in IMEM and DMEM (Gibco-Invitrogen) media, respectively, 
supplemented with 10% FBS (Hyclone-Fisher), without phenol red and 5 Ilg/ml of 
penicillin/streptomycin (Gibco) at 37°C with 5% CO2. Cells were cultured for 3 
days in complete culture media then lifted with cell-stripper (Gibco) before being 
counted with trypan blue by the Celiometer™ Auto T4 (Nexcelom Biosciences). 
Cells were seeded (5 x 105 cells per well) in 6-well plates (Corning-Fisher) 
containing 1 % serum and allowed to acclimate overnight before being treated. 
Treatments included no addition, 100 ng/ml of CXCL 12 (SCYB12; R&D 
Systems), 100 ng/ml of CXCL 12 + 100 ng/ml of pertussis toxin (List Biological 
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Laboratories}, 100 ng/ml of CXCL 12 + 6 11M of U73122 (Sigma). Cells were 
treated with inhibitors one hour prior to the addition of CXCL 12 and allowed to 
incubate for 16 hours. Media was collected and stored at -80°C and used for 
ELISA-based assays. Cells were used for total RNA isolation using the TRlzol 
method. 
Immunohistochemistry 
Tissue micro-arrays (TMAs) were deparaffinized in xylene (three changes 
5 minutes each) and rehydrated through a graded series of ethanol (100%, 95%, 
and 70%) for 5 minutes in each and washed in distilled H20. Antigen retrieval 
was performed using 0.01 M EDTA (pH 8.0) in a pressure cooker for 5 minutes. 
Slides were transferred in running water for cooling and then transferred to Tris-
buffer (pH 7.6). The endogenous peroxidase activity was blocked, by incubating 
the slides with 3% H20 2 solution for 5 minutes. The slides were then rinsed 3 
times with deionized water followed by three washes in Tris-buffer and were 
incubated with Fc block (Innovex Bioscience) for 30 minutes at room temperature 
(65°C; RT) in a humidity chamber, then incubated with 3% normal horse serum 
for 1 hour at RT to block non-specific binding. Next the sections were incubated 
for 90 minutes in a humidity chamber at RT with mouse anti-CXCR7 antibody. 
Next, the sections were washed with Tris-buffer and incubated with mouse anti-
goat antibody for 20 minutes at RT in a humidity chamber. The slides were then 
washed with Tris-buffer, treated with streptavidine peroxidase for 20 minutes at 
RT, washed with Tris-buffer, and treated with 3,3'-diaminobenzidine (DAB) for 2-
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5 minutes at RT. Subsequently, sections were washed with water, re-hydrated in 
70%, 95%, and absolute alcohol for 5 minutes each and passed through xylene 
three times for 5 minutes; and finally mounted with permount (Sigma). 
All transverse sections of tissue were scanned by a ScanScope GL 
system (Ape rio Technologies) using a 40X objective followed by loss less 
compression and assessment of all immunostainings in identical anatomic 
regions. After images from the glass slides were digitized, the resulting digital 
images were automatically analyzed using complex computer algorithms for 
standardized and unbiased controlled results. Morphometric analyses of 
sections were performed with the aid of Spectrum Plus software (Ape rio 
Technologies). Automated image analysis was performed Spectrum Plus 
algorithms for i) Positive Pixel count and Color Deconvolution for measuring and 
quantifying intensity per area for two or more stains; ii) Immunohistochemistry 
Membrane image analysis for detection of membrane-associated staining for 
individual cells and quantifies intensity and completeness (e.g., change in 
cytokeratin 5 and 8); iii) Immunohistochemistry Nuclear image analysis algorithm 
detects the nuclear staining for the individual nuclei and quantifies their intensity 
(e.g., change in the number Ki6r nuclei). 
siRNA 
Using a 6-well tissue culture plate, 2 x 105 cells per well were seeded in 
2ml antibiotic free normal growth media supplemented with 1 % FBS. Cells were 
incubated at 3JOC in a CO2 incubator until the cells were 80% confluent. Cell 
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viability was ensured before transfection with 60 pmoles of siRNA duplexes 
specific for CXCR7 (mRNA accession number NM_020311: Strand 1-
CUACACGCUCUCCUUCAUU,&rnnd2-CACUAUUGGUGUACCUUAU, and 
Strand 3- GGAUGACACUAAUUGUUAG), CXCR4 (mRNA accession number 
NM_003467: Strand 1- CUAGCUUUCUUCCACUGUU, Strand 2-
CAGAGCGUGUAGUGAAUCA, and Strand 3- GAUGGCACUUAUAACCAAA), 
control siRNA and transfection media were acquired from Santa Cruz, CA) was 
diluted into 100 III of FBS-free siRNA transfection medium. 60 pmoles of siRNA 
transfection reagent was diluted into 100 III of FBS-free siRNA trnnsfection 
medium. The siRNA duplex contained a pool of three target-specific 19 nt 
siRNAs designed to knockdown CXCR7 or CXCR4 gene expression and added 
directly to the diluted transfection reagent. The mixture was incubated for 30 
minutes at RT. Cells were washed with 2 ml of FBS-free siRNA transfection 
medium. Next, 0.8 ml of siRNA transfection medium was added to each tube 
containing the siRNA transfection reagent mixture and over-Iayed onto the 
washed cells. Cells were incubated for seven hours at 3rC in a C02 incubator. 
After seven hours, 1 ml of normal growth medium was added containing 5% FBS 
and 1 X penicillin/streptomycin without removing the transfection mixture. Cells 
were incubated for 24 hours and. assayed by RT-PCR or Amnis Imagestream to 




Human mRNA sequences for CXCR4, CXCR7, CXCL 12, MMP-1, MMP-
13, and 18S rRNA were obtained from National Center for Biotechnology 
Information (NCBI, Bethesda, MA) GenBank database. The accession numbers 
were NM003467, NM020311, NM000609, NM002421, NM005940, and 
X00686.1, respectively. These sequences were then used to design primers for 
semi-quantitative reverse transcription polymerase chain reaction (RT -PCR) 
analysis that generated amplicons of 114, 188, 168, 83, 176 and 149 bp in size 
for CXCR7, CXCR4, CXCL 12, MMP-1, MMP-13 and 18S rRNA respectively. 
Primers were designed using the Primer 3 software program 
(http://frodo.wi.mit.edu) from the Whitehead Institute at the Massachusetts 
Institute of Technology. Thermodynamic analysis of the primers was conducted 
using Primer Premier™ (Integrated DNA Technologies) and MIT Primer III. The 
resulting primer sets were compared against the entire human genome to 
confirm specificity and to ensure that the primers flanked mRNA splicing regions. 
RNA Isolation and Semi-Quantitative RT-peR 
To determine quantitatively CXCR4, CXCR7, CXCL 12, MMP-1, MMP-13, 
and 18S mRNA expression, cells were grown and treated as mentioned above 
then analyzed. Total RNA was isolated using TRlzol Reagent (Invitrogen) 
according to the manufacturer's protocol followed by precipitation with High Salt 
solution (Molecular Research Center). RNA was precipitated and resuspended 
in 27 III of RNA Secure (Ambion). Next, 1 I1g of total RNA was reverse 
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transcribed to generate cDNA using iScript reagents (BioRad Laboratories) 
according to the manufacturer's protocol. As described above, cDNA was 
amplified for gene expression using specific primers for CXCR4, CXCR7, 
CXCL 12, MMP-1, MMP-13, and 18S rRNA. For semi-quantitative PCR, all 
samples contained a reaction mixture of cDNA; specific primers (10 ng/Ill) along 
with SYBR Green polymerase chain reaction master mix (BioRad) reagents, 
according to the manufacturer's protocol. All samples were tested for the above 
listed analysts and amplified using the BioRad iQ5 Real-Time PCR Detection 
System, following predefined parameters [cycle 1: 95°C for 3 min; cycle 295°C 
for 10 sec, 60°C for 1 min (40 cycles)]. Each experiment contained treatment 
groups for HMEC, MCF-7, MDA-MB-231, and cDNA standards (106 , 105 , 104 , 
103,102, and 101 copies) for 18S rRNA. The number of copies of mRNA relative 
to 18S rRNA copies of these targets was evaluated and the number of copies for 
each target was calculated using a standard curve that was normalized to the 
number of copies of 18S rRNA expressed in each sample. Results are 
presented as the number of copies of target per 106 copies of 18S rRNA. 
Samples for gene expression were performed in duplicates and repeated twice. 
Active MMP-1 and MMP-13 detection 
To determine active MMP-1 (collagenase 1) and MMP-13 (collagenase 3) 
expression, conditioned media was collected and analyzed for each analyst. 
Flurokine (MMP-1 and MMP-13; R&D Systems) assay kits were used as 
described by the manufacturer's protocols. 
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Amnis Imagestream analysis of protein expression and localization 
PE/Cy5 conjugated anti-human CXCR4 antibody (clone#12G5) was 
purchased from Biolegend, Inc. Polyclonal rabbit anti-CXCR7 antibody was 
purchased from GeneTex, Inc and conjugated with a donkey-anti-rabbit-FITC 
antibody (R&D Systems). BrCa cells were seeded in 6-well non-adherent plates 
at 106 cells/well in media containing 1 % FBS and allowed to acclimate 3 hours 
before treatment. Cells were treated according to the above-mentioned protocols 
and cell suspensions from each well were taken at 0 and 5 minute time-points 
and collected for further analysis. Cell suspensions were centrifuged at 200 x g 
for 10 minutes at 4°C to pellet cells, supernatants were removed and cells were 
resuspended in 500 III of paraformaldehyde (PFA) / phosphate buffered saline 
(PBS) solution for 10 minutes at RT. Again, cells were centrifuged at 200 x g for 
10 minutes at 4°C to pellet cells, supernatants were removed and cells were 
resuspended in 100 III of saponin solution for 30 minutes at RT. Cell 
suspensions were centrifuged at 200 x g for 10 minutes at 4°C, supernatants 
were removed and cells were resuspended in 1 Ilg (per 106 cells) of primary 
antibody solution, which consisted of PE-Cy5-conjugated anti-mouse CXCR4, 
FITC-conjugated anti-mouse CXCR7, Alexa Fluor 488-conjugated or PE-
conjugated anti-mouse NF-kB p65, PE-conjugated anti-mouse ERK1/2 
antibodies and/or 7 AAO (BO) for 30 min at room temperature. Next, 1 ml of 
fluorescence-activated cell sorting (FACS) buffer (1 % bovine serum albumin 
(BSA) in PBS) to remove any unbound antibodies. Cell suspensions were 
centrifuged at 200 x g for 10 minutes at 4°C to pellet cells; supernatants were 
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removed and cells were resuspended in 100 111 of FACS buffer. Analyses were 
performed using Amnis ImageStream, which allows for flow cytometry-based 
image acquisition and analyses with six channels (Bright filed, dark filed, and four 
channel for different fluorochrome). This flow-based image acquisition device is 
supported by INSPIRE™ software and statistical results gathered using Amnis 
IDEASTM software (Amnis Corporation). 
The Amnis ImageStream 100 is the first commercially available imaging 
flow cytometer. It combines advantages of flow cytometry with those of image 
analysis (digital imagery of each individual cell, calculation of morphological 
changes, subcellular localization or co-localization of fluorescent probes). 
Offering several advantages over flow cytometry analysis or microscopic analysis 
of fluorescently stained cells. Simply put, the ImageStream is essentially a flow 
cytometer where photomultiplier tubes have been replaced with an array of 
sensitive charge coupled device (CCD) cameras to capture -36X images at 100 
cells per second. 
The images were stored in a compensated image file (CIF) for subsequent 
analysis using IDEAS software which quantifies change in fluorescent probe pixel 
intensities in: area of mask in pixels, aspect ratio of mask, weighted aspect ratio 
of mask, mean intensity of pixels outside of mask, standard deviation of intensity 
of pixels outside of mask, centroid of mask in horizontal axis, intensity-weighted 
centroid of mask in horizontal axis, centroid of mask in vertical axis, intensity-
weighted centroid of mask in vertical axis, total intensity of image using logical 
"OR" of all six image masks, variance of intensity of pixels within masks, 
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maximum intensity gradient of pixels within mask, radius mean square (RMS) of 
intensity gradient of pixels within mask, background-corrected sum of pixel 
intensities within mask, major axis of mask in pixels, intensity-weighted major 
axis of mask in pixels, total Intensity of image divided by area of mask, minimum 
pixel intensity within mask, minor axis of mask in pixels, intensity-weighted minor 
axis of mask in pixels, angle of major axis relative to axis of flow, angle of 
intensity-weighted major axis relative to axis of flow, maximum pixel intensity 
within mask, number of edge pixels in mask, maximum pixel intensity within large 
bright spots, sum of pixel intensities within large bright spots, maximum pixel 
intensity within medium-sized bright spots, sum of pixel intensities within 
medium-sized bright spots, un-normalized maximum pixel intensity within large 
bright spots, sum of un-normalized pixel intensities within large bright spots, 
maximum pixel intensity within small bright spots, sum of pixel intensities within 
small bright spots, sum of pixel intensities within mask, number of spots detected 
in image, area of logical "OR" of all six image masks in pixels, camera line 
readout rate in Hertz at time object was imaged, unique object number, pixel 
intensity correlation between two images of the same object, and user-defined 
algebraic combination of imagery and masks, user-defined masks using (erode, 




To interpret our results, significance tests and statistical analysis were 
used for each experiment. The traditional a-value, i.e., p = 0.01, was used to 
evaluate the statistical significance of each study. The power of these studies 
was determined by the probability (1-~) of detected significant difference (0) 
between control and experimental groups. The data were expressed as the 
mean ± SEM and compared using a two-tailed paired (or unpaired) student's t-




The Expression of CXCR7 by Breast Tumors 
Prior studies in our laboratory and others have shown chemokine receptor 
expression by various carcinomas (74, 106). I confirmed in vivo protein 
expression of CXCR7 by breast tumor tissue. Immunohistochemistry was 
performed using deparaffinized TMAs stained with DAB (brown), which is 
representative of CXCR7, and counterstained with hematoxylin (Figure 3). 
CXCR7 expression was elevated in breast tumors staged asT1 (n = 10), T2 (n = 
40), T3 (n = 15), and T4 (n = 4) and compared with non-neoplastic breast tissue 
from the same subject (i.e., n = 69). CXCR7 expression was significantly higher 
in all breast tumor tissue than compared to benign tissue and highest in T 4 > T1 , 
T2, and T3 staged tumor tissue. While expression of CXCR7 in breast tumors 
did not correlate with stage, a trend of cytoplasmic to nucleur localization of 
CXCR7 expression was observed when comparing early stage with advanced 
stage cases, respectively. 
CXCR7 mRNA Expression in BrCa Cells 
To determine whether chemokine/chemokine receptor interactions are 
involved in BrCa cell progression, I performed comprehensive and quantitative 
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Figure 3. Relative CXCR7 Expression by non-neoplastic and malignant 
breast tissues. Previously evaluated samples were stained for CXCR7. 
Relative CXCR7 expression (i.e. , colorimetric intensity) ± SO by non-neoplastic 
(n = 4) breast tissue and T1 (n = 10), T2 (n = 40), T3 (n = 15), and T4 (n = 2) 
staged tumors are shown in the left panel. Representative CXCR7 (DAB-brown) 
and hemotoxylin-counter-stained (20X magnification) sections are shown in the 
right panels. 
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PR+ and HER2+) and MDA-MB-231 (ER, PR- and HER2-) and compared the 
expression of these chemokine receptors to HMECs. Absolute mRNA levels 
were determined using semi-quantitative RT -PCR that showed that CXCR7 and 
CXCR4 were expressed in the BrCa cells (untreated) being investigated. Three 
different patterns of receptor expression were observed when comparing primary 
HMECs to the BrCa cell lines. First, both CXCR7 and CXCR4 mRNA expression 
was relatively low in HMEC (Figure 4). Second, CXCR7 mRNA expression was 
elevated in MCF-7 cells, with CXCR4 mRNA expression being moderately 
elevated. With regard to the more aggressive BrCa cell line, MDA-MB-231, 
CXCR4 mRNA expression was highly elevated, with CXCR7 being low. These 
findings demonstrated the elevated, yet differential, expression of CXCR7 and 
CXCR4 mRNAs in BrCa cell lines, compared to normal breast epithelial cell lines. 
Amnis ImageStream confirmed strong CXCR7 and CXCR4 protein, cell-
surface expression by primary human mammary epithelial cells (HMECs) (Figure 
5) and MCF-7 and MDA-MB-231 cell lines (Figures 6). Cell density plots, which 
analyzed both positive and negative events of each receptor, show the 
percentage of cells that were positive either for CXCR7, CXCR4, or both 
receptors. The percent distribution displayed in each cell density plot was based 
on the intensity of each receptor's protein expression. These findings 
demonstrate that CXCR4 and CXCR7 protein expression does not precisely 



























Figure 4. Relative CXCR4 and CXCR7 mRNA expression by BrCa cell lines 
and HMECs. Total RNA was isolated from primary breast (HMEC) and BrCa cell 
lines MDA-MB-231 and MCF-7. Semi-quantitative RT-PCR analysis of 
chemokine receptor mRNA expression was performed in triplicates. The copies 
of transcripts were expressed relative to actual copies of 18S rRNA. Asterisk(s) 
indicate statistical significance (p < 0.05) between HMEC, MCF-7 and MDA-MB-
231 cells. 
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Figure 5. Protein expression and cellular distribution of CXCR4 and CXCR7 
by HMECs. Primary breast epithelial cells were stained with polyclonal-rabbit 
anti-CXCR7 antibody conjugated with donkey-anti-rabbit-FITC and PE/Cy5 anti-
human CXCR4 antibody. After staining, cells were washed with FACS buffer and 
analyzed. 7-AAD was used to stain the nucleus and positive stained cells were 
quantified by Amnis ImageStream. Image analyses were performed using Image 
Data Exploration Analysis Software (IDEAS). The panel on the left is a density 
plot of the cell population that was positively stained for CXCR4 and CXCR7. 
The panel on the right from left to right is 7-AAD (red) , CXCR7 (green) , CXCR4 
(purple) , and composite , respectively. 
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Figure 6. Protein expression and cellular distribution of CXCR4 and CXCR7 
by BrCa cell lines. MCF-7 and MDA-MB-231 cells were stained with polyclonal-
rabbit anti-CXCR7 antibody conjugated with donkey-anti-rabbit-FITC and PE/Cy5 
anti-human CXCR4 antibody. After staining, cells were washed with FACS buffer 
and analyzed. 7-AAD was used to stain the nucleus and quantified using Amnis 
Imagestream System. Image analyses were performed using Image Data 
Exploration Analysis Software (IDEAS). Top panels show density plots of cell 
populations. Bottom panels from left to right is 7-AAD (red) , CXCR7 (green) , 
CXCR4 (purple) , and composite respectively. 
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suggest post-transcriptional and/or -translational modification of chemokine 
receptors may occur, which would not doubt effect their function. 
Receptor expression during the cell cycle as well as translocation was 
also determined using untreated BrCa cells. MCF-7 and MDA-MB-231 cell lines 
showed high expression of both CXCR7 and CXCR4 in G2 phase of the cell 
cycle, with moderate to low expression for S and comparatively low expression 
during GoIG1 phases (Figure 7). HMECs showed a similar pattern. 
Interestingly, this pattern of chemokine receptor expression supports the notion 
that chemokine receptor signaling during the cell cycle might promote cell 
survival and proliferation. It is important to mention that while CXCR4 expression 
is largely confined to the cytoplasm during BrCa progression, the expression of 
CXCR7 is localized to tumor cell nuclei for advanced BrCa cases (Figure 3). 
When comparing BrCa cell lines and HMECs, CXCR4 and CXCR7 translocated 
to the nucleus of cells after CXCL 12 stimulation (Figures 8,9, and 10). Taken 
together, CXCR4 and CXCR7 expression and cellular distribution correlates with 
advanced BrCa stage and CXCL 12 stimulation of BrCa cells. 
Regulation of endogenous CXCR4 and CXCR7 expression 
A major breakthrough in gene regulation came with the observation that 
siRNA of 21 nucleotides (nt) in length that mimic Dicer cleavage products can 
efficiently induce sequence-specific gene silencing when transiently transfected 
into mammalian cells (107, 108). To genetically knockdown CXCR4 and CXCR7 
expression by MCF-7 and MDA-MB-231 cell lines, I used siRNA nucleotides that 
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Figure 7. CXCR4 and CXCR7 expression by primary mammary and BrCa 
cell lines. HMEC cells as well as MCF-7 and MDA-MB-231 cell lines were 
stained with polyclonal-rabbit anti-CXCR7 antibody conjugated with donkey-anti-
rabbit-FITC and PE/Cy5 anti-human CXCR4 antibody. After staining, cells were 
washed with FACS buffer and analyzed. 7-AAD was used to stain the nucleus 
and positive stained cells were quantified by Amnis ImageStream. Image 
analyses were performed using IDEAS. Histograms represent cell populations 
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Figure 8. Expression and non-nucleus distribution CXCR4 and CXCR7 in 
resting primary mammary and BrCa cells. HMEC as well as MCF-7 and 
MDA-MB-231 cell lines were stained with polyclonal-rabbit anti-CXCR7 antibody, 
FITC-conjugated donkey-anti-rabbit antibody, and PE/Cy5-conjugated anti-
human CXCR4 antibody. After staining, cells were washed with FACS buffer and 
analyzed. 7-AAD was used to stain the nucleus. Subsequently, cells were 
quantified by Amnis ImageStream. Image analyses were performed using 
IDEAS. The left panels show the spatial ratio of chemokine receptor and nuclei 
intensities as a histogram representing CXCR4 or CXCR7 and nucleus 
localization or translocation. 
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Figure 9. CXCR4 and CXCR7 cytoplasmic to nuclear translocation and 
expression by MCF-7 cells. MCF-7 cells were treated with 100 ng/ml of 
CXCL 12 for 5 minutes and stained with polyclonal-rabbit anti-CXCR7 antibody, 
FITC-conjugated donkey-anti-rabbit antibody, and PE/Cy5-conjugated anti-
human CXCR4 antibody. After staining, cells were washed with FACS buffer and 
analyzed. 7-AAD was used to stain the nucleus. Subsequently, cells were 
quantified by Amnis ImageStream. Image analyses were performed using 
IDEAS. The left panels show the spatial ratio of chemokine receptor and nuclei 
intensities as a histogram representing CXCR4 or CXCR7 and nuclear 
localization or translocation. The right panel shows representative images of the 
major cell population. 
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Figure 10. CXCR4 and CXCR7 cytoplasmic to nuclear translocation and 
expression by MDA-MB-231 cells. MDA-MB-231 cells were treated with 100 
ng/ml of CXCL 12 for 5 minutes and stained with polyclonal-rabbit anti-CXCR7 
antibody, FITC-conjugated donkey-anti-rabbit antibody, and PE/Cy5-conjugated 
anti-human CXCR4 antibody. After staining, cells were washed with FACS buffer 
and analyzed. 7-AAD was used to stain the nucleus. Subsequently, cells were 
quantified by Amnis ImageStream. Image analyses were performed using 
IDEAS. The left panels show the spatial ratio of chemokine receptor and nuclei 
intensities as a histogram representing CXCR4 or CXCR7 and nuclear 
localization or translocation. The right panel shows representative images of the 
major cell population. 
43 
targeted human CXCR4 and CXCR7 mRNA. siRNAs were transiently 
transfected into BrCa cells for 24 hours using the above mentioned protocol 
before being pre-treated with or without inhibitors (100 ng/ml of pertussis toxin or 
6 /.!M of U-73122) 1 hour prior to 100 ng/ml of CXCL 12 for 16 hours. The siRNA 
transfection efficiency was determined by Western Blot analyses and Amnis 
ImageStream (data not shown). As expected, CXCR4- or CXCR7-specific siRNA 
treatment completely abrogated CXCR4 or CXCR7 mRNA expression, 
respectively, in both BrCa cell lines (Figures 11 and 12). 
CXCL 12 treatment significantly increased the expression of CXCR7 
mRNA, but not CXCR4 mRNA, by MDA-MB-231 cells without having an effect on 
MCF-7 cells. Moreover, CXCL 12 treatment did not effect CXCR4 mRNA 
expression by either cell line. Pertussis toxin inhibited the CXCL 12-mediated 
CXCR7 mRNA upregulation; whereas, U-73122 did not (Figure 13). However, in 
MDA-MB-231 BrCa cells, both pertussis toxin and U-73122 were able to inhibit or 
completely abrogate CXCL 12-dependent CXCR7 mRNA expression (Figure 14). 
CXCL 12 stimulation of MDA·MB·231 cells also enhanced their expression of 
CXCL 12 mRNA (Figure 15), when compared to untreated cells. This 
expression; however, was inhibited by CXCR4- and CXCR7-specific siRNA as 
well as by pertussis toxin and U-73122 treatment. CXCL 12 treatment of MCF-7 
cells also resulted in a measurable increase in CXCL 12 mRNA expression, but 
this effect was enhanced by CXCR4, CXCR7, and G~/Gy protein inhibition, but 
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Figure 11. CXCR4 and CXCR7 mRNA expression by MCF-7 cells. Total RNA 
was isolated from BrCa cells pretreated with or without 60 pmoles of CXCR4- or 
CXCR7-specific siRNA in the presence or absence of 100 ng/ml CXCL 12 for 16 
hours. Semi-quantitative RT-PCR analysis of CXCR4 and CXCR7 mRNA 
expression was performed in triplicate. The copies of transcripts were expressed 
relative to copies of 18S rRNA. Asterisk(s) indicate statistical significance (p < 
0.05) between treatment groups. 
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Figure 12. CXCR4 and CXCR7 mRNA expression by MDA-MB-231 cells. 
Total RNA was isolated from BrCa cells pretreated with or without 60 pmoles of 
CXCR4- or CXCR7-specific siRNA in the presence or absence of 100 ng/ml 
CXCL 12 for 16 hours. Semi-quantitative RT -PCR analysis of CXCR4 and 
CXCR7 mRNA expression was performed in triplicate. The copies of transcripts 
were expressed relative to copies of 18S rRNA. Asterisk(s) indicate statistical 
significance (p < 0.05) between treatment groups. 
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Figure 13. Ga and G~/G'Y protein-dependent CXCR7 and CXCR4 mRNA 
expression by MCF-7 cells. Total RNA was isolated from BrCa cells pretreated 
with or without CXCR4- or CXCR7-specific siRNA and/or pertussis toxin and U-
73122 in the presence or absence of 100 ng/ml CXCL 12 for 16 hours. Semi-
quantitative RT-PCR analysis of CXCR7 and CXCR4 mRNA expression was 
performed in triplicates. The copies of transcripts were expressed relative to 
actual copies of 18S rRNA. Asterisk(s) indicate statistical significance (p < 0.05) 
between treatment groups. 
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Figure 14. Ga and G~/G'Y protein-dependent CXCR7 and CXCR4 mRNA 
expression by MDA-MB-231 cells. Total RNA was isolated from BrCa cells 
pretreated with or without CXCR4- or CXCR7 -specific siRNA and/or pertussis 
toxin and U-73122 in the presence or absence of 100 ng/ml CXCL 12 for 16 
hours. Semi-quantitative RT-PCR analysis of CXCR7 and CXCR4 mRNA 
expression was performed in triplicates. The copies of transcripts were 
expressed relative to actual copies of 18S rRNA. Asterisk(s) indicate statistical 
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Figure 15. Ga and G~/G'Y protein-dependent CXCL 12 mRNA expression by 
MDA-MB-231 cells. Total RNA was isolated from BrCa cells pretreated with or 
without CXCR4- or CXCR7-specific siRNA and/or pertussis toxin and U-73122 in 
the presence or absence of 100 ng/ml CXCL 12 for 16 hours. Semi-quantitative 
RT-PCR analysis of CXCL 12 mRNA expression was performed in triplicates. 
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Figure 16. Ga and G~/G'Y protein-dependent CXCL 12 mRNA expression by 
MCF-7 cells. Total RNA was isolated from BrCa cells pretreated with or without 
CXCR4- or CXCR7-specific siRNA and/or pertussis toxin and U-73122 in the 
presence or absence of 100 ng/ml CXCL 12 for 16 hours. Semi-quantitative RT-
PCR analysis of CXCL 12 mRNA expression was performed in triplicates. The 
copies of transcripts were expressed relative to actual copies of 18S rRNA. 
Asterisk(s) indicate statistical significance (p < 0.05) between untreated and 
treated groups. 
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complexity of CXCL 12-CXCR4/7 interactions, but demonstrated CXCL 12 
stimulation of BrCa cells results in the suppression of CXCL 12 mRNA expression 
that was most likely dependent on a Gai protein. 
CXCL 12 is a powerful chemo-attractant that stimulates bi-directional 
migration, invasion, and survival of breast cancer cells (109). I examined 
whether the interactions of CXCL 12-CXCR417 are involved in signal-transduction 
pathways that lead to these events. Previous studies have shown that 
phosphorylation of ERK1/2 in lung cancer cells is involved in cell migration and 
invasion (110). Other studies have shown that NF-kB activation is necessary for 
cell migration and invasion of other cancer cells (111). To determine if ERK1/2 
and NF-kB are activated by CXCRL 12, in vitro assays followed by Amnis 
ImageStream analysis were performed. Untreated HMECs and BrCa cell lines 
expressed moderate to high protein levels of phosphorylated ERK1/2 and NF-kB 
in the cytosol (Figures 17 and 18). After CXCL 12 stimulation, both 
phosphorylated NF-kB and ERK1/2 translocated to the nucleus of BrCa cell lines 
(Figures 19 and 20). This demonstrates that detection of CXCL 12 by CXCR4 
and/or CXCR7 transduces cell signals leading to the activation of both ERK1/2 
and NF-kB and their translocation to the nucleus. 
Liang et 81. recently demonstrated that silencing of CXCR4 expression in 
BrCa cells successfully blocks metastasis to various organs. Here, I sought to 
determine if down regulating CXCR7, CXCR4, or both of their mRNA levels using 
siRNA would inhibit either activation of ERK1/2 and NFkB or their translocation to 
cell nuclei. CXCR4- and CXCR7-specific gene silencing lead to complete 
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Figure 17. NF-lCB and ERK1/2 cytoplasmic to nuclear translocation and 
expression by HMECs. HMECs were stained with Alexa Fluor 488-conjugated 
mouse anti-NF-KB p65 and PE-conjugated mouse anti-ERK1/2 antibodies. 7-
AAD was used to stain the nucleus. Subsequently, cells were characterized by 
Amnis ImageStream analysis. Image analyses were performed using IDEAS. 
The left panels show the spatial ratio of chemokine receptor and nuclei intensities 
as a histogram representing NF-KB or ERK1/2 and nucleus localization or 
translocation. The right panel shows representative 7-AAD (red) , NF-KB (green), 
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Figure 18. NF-KB and ERK1I2 activation state and cellular distribution by 
resting BrCa cells. MCF-7 and MDA-MD-231 cell lines were stained with Alexa 
Fluor 488-conjugated mouse anti-NFKB p65 and PE-conjugated mouse anti-
ERK1/2 antibodies. 7-AAD was used to stain the nucleus. Subsequently, 
images of cells were acquired by Amnis ImageStream and analyzed using 
IDEAS software. The top panels show the spatial ratio of NFKB, ERK1/2, and 
nuclei intensities and co-localization as a histogram. The bottom panel shows 
representative 7-AAD (red), NF-KB (green) , ERK1/2 (orange) , and composite 
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Figure 19. NF-KB and ERK1I2 expression and cytoplasmic to nuclear 
translocation by CXCL 12-treated MCF-7 cells. MCF-7 cells were stained with 
Alexa Fluor 488-conjugated mouse anti-NFKB p65 and PE-conjugated mouse 
anti-ERK1/2 antibodies_ 7-AAD was used to stain the nucleus. Subsequently, 
images of cells were acquired by Amnis ImageStream and analyzed using 
IDEAS software. The top panels show the spatial ratio of NFKB, ERK1/2, and 
nuclei intensities and co-localization as a histogram. The bottom panel shows 
representative 7-AAD (red) , NF-KB (green) , ERK1/2 (orange) , and composite 
images of the major cell populations_ 
54 
7·AAO NFk~5 ERK1n Composite 
C' 
~ 0 3 5 9 






Similarity: 1AAD: NFIcS 
Figure 20. NF-KB and ERK1/2 expression and cytoplasmic to nuclear 
translocation by CXCL 12-treated MDA-MB-231 cells. MDA-MB-231 cells 
were stained with Alexa Fluor 488-conjugated mouse anti-NFKB p65 and PE-
conjugated mouse anti-ERK1/2 antibodies. 7-AAD was used to stain the 
nucleus. Subsequently, images of cells were acquired by Amnis ImageStream 
and analyzed using IDEAS software. The top panels show the spatial ratio of 
NFKB, ERK1/2 , and nuclei intensities and co-localization as a histogram. The 
bottom panel shows representative 7-AAD (red) , NF-KB (green) , ERK1/2 
(orange) , and composite images of the major cell populations (Figures 21 and 
22). 
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inhibition of CXCL 12-mediated ERK1/2 and NF-kB translocation to cell nuclei. 
Similarly, Gai protein inhibition using pertussis toxin and GWGy protein inhibition 
using U-73122, regardless of CXCR4 or CXCR7 expression also abrogated 
ERK1/2 and NF-kB cytoplasmic to nucleur translocation (Figures 23 and 24). 
Moreover, these observations were performed in triplicates and at several time 
points that demonstrated that the response to CXCL 12 is rapid. 
CXCL12-CXCR4ICXCR7 interactions mediating MMP-1 and MMP-13 
expression 
Previous studies in our laboratory demonstrated MMP mRNA expression 
and protein activity by prostate cancer cells was modulated by CXCL 12-CXCR4 
interactions (74). Others have shown that the timely breakdown of the 
extracellular matrix (ECM) is essential for breast cancer metastasis (64, 112). 
CXCL 12 has also been suggested to induce MMP expression in breast cancer 
cells through CXCR4 (113). Here, I examined the induction of MMP-1 and MMP-
13 by BrCa cells after CXCL 12 stimuli. CXCL 12 stimulation of MDA-MB-231 
cells caused increases in MMP-1 mRNA and the down regulation of MMP-13 
mRNA expression and moderate to low expression of MMP-13 and MMP-1 by 
similarly treated MCF-7 cells (Figure 25). Pertussis toxin or U-73122 
pretreatment lead to inhibition of both MMP-1 and MMP-13 mRNA expression. 
To determine if the observed CXCL 12-mediated effects on collagenase 
expression and activity were dependent on CXCR4 or CXCR7, these chemokine 
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Figure 21. CXCR4-dependent NF-KB and ERK1I2 expression and 
cytoplasmic to nuclear translocation by CXCL 12-treated BrCa cell lines. 
CXCR4-specific siRNA-pretreated MDA-MB-231 and MCF-7 cells were 
stimulated with CXCL 12 and stained with Alexa Fluor 488-conjugated mouse 
anti-NFKB p65 and PE-conjugated mouse anti-ERK1/2 antibodies. 7-AAD was 
used to stain the nucleus. Subsequently, images of cells were acquired by 
Amnis ImageStream and analyzed using IDEAS software. The top panels show 
the spatial ratio of NFKB, ERK1/2, and nuclei intensities and co-localization as a 
histogram. The bottom panel shows representative 7-AAD (red), NF-KB (green), 
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Figure 22. CXCR7-dependent NF-KB and ERK1I2 expression and 
cytoplasmic to nuclear translocation by CXCL 12-treated BrCa cell lines. 
CXCR7-specific siRNA-pretreated MDA-MB-231 and MCF-7 cells were 
stimulated with CXCL 12 and stained with Alexa Fluor 488-conjugated mouse 
anti-NFKB p65 and PE-conjugated mouse anti-ERK1/2 antibodies. 7-AAD was 
used to stain the nucleus. Subsequently, images of cells were acquired by 
Amnis ImageStream and analyzed using IDEAS software. The top panels show 
the spatial ratio of NFKB, ERK1/2, and nuclei intensities and co-localization as a 
histogram. The bottom panel shows representative 7-AAD (red), NF-KB (green), 
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Figure 23. CXCR4-, Gai protein-, and G~ protein I Gy protein-dependent NF-
lCB and ERK1I2 expression and cytoplasmic to nuclear translocation by 
CXCL 12-treated BrCa cell lines. CXCR4-specific siRNA-, pertussis toxin-, 
and/or U-73122-pretreated MDA-MB-231 and MCF-7 cells were stimulated with 
CXCL 12 and stained with Alexa Fluor 488-conjugated mouse anti-NFKB p65 and 
PE-conjugated mouse anti-ERK1/2 antibodies. 7-AAD was used to stain the 
nucleus. Subsequently, images of cells were acquired by Amnis ImageStream 
and analyzed using IDEAS software. The top panels show the spatial ratio of 
NFlCB, ERK1/2, and nuclei intensities and co-localization as a histogram. The 
bottom panel shows representative 7-AAD (red), NF-KB (green), ERK1/2 
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Figure 24. CXCR7-, Gai protein-, and G~ protein I Gy protein-dependent NF-
x:B and ERK1/2 expression and cytoplasmic to nuclear translocation by 
CXCL 12-treated BrCa cell lines. CXCR7-specific siRNA-, pertussis toxin-, 
and/or U-73122-pretreated MDA-MB-231 and MCF-7 cells were stimulated with 
CXCL 12 and stained with Alexa Fluor 488-conjugated mouse anti-NFx:B p65 and 
PE-conjugated mouse anti-ERK1/2 antibodies. 7-AAD was used to stain the 
nucleus. Subsequently, images of cells were acquired by Amnis ImageStream 
and analyzed using IDEAS software. The top panels show the spatial ratio of 
NFx:B, ERK1/2, and nuclei intensities and co-localization as a histogram. The 
bottom panel shows representative 7-AAD (red), NF-x:B (green), ERK1/2 
(orange), and composite images of the major cell populations. 
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Figure 25. Ga and G~/G'Y protein-independent MMP-1 and MMP-13 mRNA 
expression by Brea cell lines. Total RNA was isolated from BrCa cells 
pretreated with or without pertussis toxin and U-73122 in the presence or 
absence of CXCL 12 for 16 hours. Semi-quantitative RT-PCB analysis of 
CXCL 12 mRNA expression was performed in triplicates. ThH copies of 
transcripts were expressed relative to actual copies of 18S rHNA. Asterisk(s) 
indicate statistical significance (p < 0.05) between untreated and treated groups. 
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presumably enhanced CXCL 12-dependent induction of MMP-13 mRNA 
expression through selective CXCR7 signaling in MCF-7 cells (Figures 15 and 
26). This CXCL 12-CXCR7 interactions were not affected by pertussis toxin, but 
U-73122 with selective CXCL 12-CXCR7 signaling greatly reduced MMP-13 
mRNA expression but enhanced MMP-1 mRNA expression. Interestingly, 
CXCR7 silencing, which allowed for selective CXCL 12-CXCR4 signaling resulted 
in the enhancement of MMP-1 and MMP-13 mRNA expression by MCF-7 cells. 
The more aggressive BrCa cell line, MDA-MB-231, produced MMP-13 but 
not MMP-1 mRNA (Figures 16 and 27). CXCL 12 treatement of these cells 
abrogated MMP-13 mRNA expression while greatly enhancing MMP-1 mRNA 
expression. CXCR4-specific siRNA abrogated expression of both MMP-1 and 
MMP-13, even after CXCL 12 treatment. However, CXCR7 inhibition augmented 
the endogenous expression of MMP-13 mRNA, but not MMP-1 mRNA. Pertussis 
toxin and U-73122 treatment inhibited the ability of CXCL 12 to modulate MMP-1 
and MMP-13. 
MMP-1 and MMP-13 active protein assays were performed to confirm the 
above mentioned findings regarding mRNA expression. CXCL 12 treatment 
increased active MMP-1 and MMP-13 protein expression by MCF-7 and MDA-
MB-231 cells (Figures 17 and 28). CXCR4 inhibition suppressed the functional 
activity of MMP-1 and MMP-13 in both BrCa cell lines. However, siRNA silencing 
of CXCR7 gene expression resulted in an up regulation of MMP-1 activity by 
MCF-7 cells following CXCL 12 stimulation. Both pertussis toxin and U-73122 
inhibited the increase in active MMP-1 and MMP-13 expressed by MCF-7 and 
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Figure 26. CXCR4- and CXCR7-dependent MMP-1 and MMP-13 mRNA 
expression by MCF-7 cells. Total RNA was isolated from MCF-7 cells 
pretreated with or without CXCR4 siRNA, CXCR7 siRNA, pertussis toxin , and U-
73122 in the presence or absence of CXCL 12 for 16 hours. Semi-quantitative 
RT-PCR analysis of MMP-1 and MMP-13 mRNA expression was performed in 
triplicate. Copies of transcripts were expressed relative to copies of 18S rRNA. 
Asterisk(s) indicate statistical significance (p < 0.05) between untreated and 
treated groups. 
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Figure 27. CXCR4- and CXCR7-dependent MMP-1 and MMP-13 mRNA 
expression by MDA-MB-231 cells. Total RNA was isolated from MDA-MB-231 
cells pretreated with or without CXCR4 siRNA, CXCR7 siRNA, pertussis toxin, 
and U-73122 in the presence or absence of CXCL 12 for 16 hours. Semi-
quantitative RT-PCR analysis of MMP-1 and MMP-13 mRNA expression was 
performed in triplicate. Copies of transcripts were expressed relative to copies of 
18S rRNA. Asterisk(s) indicate statistical significance (p < 0.05) between 
untreated and treated groups. 
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Figure 28. CXCR4- and CXCR7-dependent MMP-1 and MMP-13 active 
protein expression by BrCa cell lines. Total RNA was isolated from MDA-MB-
231 and MCF-7 cells pretreated with or without CXCR4 siRNA, CXCR7 siRNA, 
pertussis toxin, and U-73122 in the presence or absence of CXCL 12 for 16 
hours. Culture supernatants were assayed for MMP-1 and MMP-13 activity and 
performed in duplicate. MMP activity is expressed as relative fluorescence units. 
Asterisk(s) indicate statistical significance (p < 0.05) between untreated and 
treated groups. 
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MDA-MB-231 BrCa cells following CXCL 12 stimulation. Interestingly, siRNA 
CXCR4 plus U-73122 pretreatment showed a slight increase that was similar to 




BrCa is a leading cause of cancer morbidity and mortality among women 
and with a yearly toll of more than 40,170 deaths in the US alone. Its etiology is 
based upon a distinct pattern of metastasis involving regional lymph nodes, bone 
marrow, lung and liver (114). Although much has been done to improve the 
understanding of the underlying mechanisms for oncogenic transformation that 
leads to tumor initiation, much less is known about the processes regulating 
BrCa metastasis. However, it has been postulated that BrCa cell metastasis is 
highly influenced and facilitated by tumor microenvironmental cues that render an 
otherwise non-invading cell metastatic (115). Cell signaling is ostensibly 
supplied by the stromal component of breast carcinomas which is made up of a 
network of cells including: CAFs, myofibroblasts, lymphocytes, tumor associated 
macrophages, pericytes, dendritic cells, mesenchymal cell types, and endothelial 
cells (116). At the cellular level, metastasis is an intricate and complex, multi-
step process that is dependent on a variety of factors. Further, a permissive 
microenvironment is required for successful metastasis of breast cancer cells. 
Specifically, the microenvironment of the primary tumor needs to support tumor 
cell dissemination, motility, and invasion into the vasculature. The 
microenvironment at the secondary site needs to support cell adhesion, 
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proliferation, neovascularization, and survival (117). Other mechanisms in which 
breast tumor microenvironment can influence metastatic potential include the 
following: remodeling of the extracellular matrix (ECM) and changes in 
glycoprotein composition which can alter cell adhesion, motility, proliferation, 
apoptotic rates, degradation of the extracellular matrix via proteinase activity 
within the stroma which helps with tumor cell migration by disrupting stromal 
barriers; and lastly, the release of bioactive extracellular fragments and growth 
factors that can promote or suppress neoplastic progression of both stromal and 
breast tumor cells (118). In this regard, chemokines and their receptors have 
been implicated to play critical roles in mediating the mechanisms necessary for 
breast cancer cell metastasis. Further, cell signaling through chemokine 
receptors i.e. CXCR4 mediates actin polymerization and pseudopodia formation 
in breast cancer cells and induces chemotactic and invasive responses (114). In 
addition, it has been shown that organs representing secondary sites of breast 
cancer metastasis are the most abundant sources of chemokine ligands e.g. 
CXCL 12 for their tumor-associated receptors. 
The purpose of this study was to investigate the role of CXCR7/CXCR4 
and CXCL 12 interactions in mediating breast cancer cell progression. The 
experiments in this study determined the expression of CXCR7 and CXCR4, their 
responsiveness to CXCL 12, and the ability of siRNA interference along with 
inhibitors pertussis toxin and U-73122 to alter gene expression and/or CXCL 12-
mediated molecular signals. I performed comprehensive quantitative and 
qualitative analysis of the expression of CXCR7, CXCR4 as well as CXCL 12 in 
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two different breast cancer cell lines, MCF-7 (ER+, PR+, Her2+) and MDA-MB-
231 (ER-, PR-, Her2-). Human primary mammary epithelial cell line (HMEC) was 
used as the control. 
Preliminary immunohistochemistry analysis demonstrated elevated 
CXCR7 protein expression in breast cancer tumors. Further, its protein 
expression remained elevated throughout stages 1, 2, and 3 but peaking in tumor 
stage 4. Also, there was an observation of CXCR7 protein expression moving 
from the cytoplasm of these tumors to the nucleus. This is suggestive of a role in 
nuclear signaling for this particular GPCR. The biological importance of this may 
be considered on various levels. However, the most significant is that studies 
have shown that only a select group of GPCRs can translocate from the plasma 
membrane to nuclear membranes upon activation and constitute complexes that 
sense and transduce distinctive signals in relation to the intracellular levels of 
their cognate ligand (119). The subsequent nuclear signal may have different or 
even opposite cellular effects than the original signal. Thus, current research 
must elucidate the characteristics of GPCR nuclearization and how this separate 
signaling pathway affects cellular events. 
Semi-quantitative RT -PCR analyses showed that breast cancer cells do 
express chemokine receptors CXCR7 and CXCR4; however, their expression 
was cell-type specific. For example, in the MCF-7 (ER+, PR+, Her2+) breast 
cancer cell line, CXCR7 mRNA expression was 2-fold higher than CXCR4 mRNA 
expression. In the more aggressive breast cancer cell line MDA-MB-231 (ER-, 
PR-, Her2-), CXCR4 mRNA expression was 3-fold higher than CXCR7 mRNA 
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expression. With regard to the human primary mammary epithelial cell line, only 
CXCR7 mRNA was detected. 
Having established that BrCa cells expressed functionally active CXCR7 
and CXCR4, I evaluated protein expression of CXCR7 and CXCR4 on BrCa 
cells. Amnis ImageStream analysis demonstrated both CXCR7 and CXCR4 
protein expression on primary mammary and BrCa cells. Density plots, which 
allow for analysis of positive and negative events of cells stained for each 
receptor, showed that 84.1 % of the cells (HMEC) were double positive for both 
receptors, while 11.13% followed by 3.46% were singly positive for CXCR7 and 
CXCR4 respectively. Concerning MCF-7, at least 85.9% of the cells were double 
positive for both receptors while 10.4% followed by 2.2% were singly positive for 
CXCR7 and CXCR4 respectively. 88.6% of MDA-MB-231 cells were positive for 
both receptors while 9.6% followed by 1.8% were selectively positive for CXCR4 
and CXCR7, respectively. Image analyses of these breast cancer cells showed 
CXCR7 protein expression just below the cell membrane. These findings are 
consist with earlier studies that demonstrated intracellular pools of CXCR7 on T 
lymphocytes (120). 
CXCR4 protein expression by MCF-7 was uniformly distributed along the 
cell surface and in MDA-MB-231 cells; it was concentrated just below the cell 
membrane. These findings would suggest that cellular distribution of 
CXCR4/CXCR7 is important for their functional responses as well as signal 
transduction pathways induced by CXCL 12 stimulation. Also, this is consistent 
with the histology data that demonstrated CXCR7 transition from the cytoplasm 
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to the nucleus of breast tumors. These site-dependent differences of CXCR4 
and CXCR7 distribution might provide key advantages for cellular signaling and 
intracellular movement involved in breast cancer progression. 
The current paradigm suggests that increased CXCR4 expression dictates 
the ability of breast carcinoma cells to metastasize to organs such as the bone 
marrow, lung, and liver that express high amounts of CXCL 12 (23). CXCL 12 
engages both CXCR4 and CXCR7 to regulate this pathological process. Here, I 
demonstrated that both CXCR4 and CXCR7 are expressed on breast cancer 
cells and how they cooperate to respond to CXCL 12 is not well understood. 
Moreover, it has been shown that CXCR4 occupied by CXCL 12 is able to 
activate heterotrimeric G-proteins that trigger several downstream events, 
calcium mobilization, actin polymerization, integrin-mediated adhesion, gene 
transcription, and proliferation. Further, kinetic analysis of CXCR4 activation 
determined that part of the receptor constitutively interact with inactive, GDP-
bound Ga subunits so that G-protein activation arises from conformational 
changes within preassembled receptor G-protein complexes. These complexes 
do not disassemble after activation but persist over time (121, 122). Together, 
these findings suggest CXCR7 constitutively interacts with G-proteins, but fails to 
activate them or mobilize intracellular calcium once engaged by CXCL 12. 
In this study, I postulated that CXCR7 cell signaling involved a pathway 
that was independent of G protein(s) signal transduction. Indeed, CXCR7 
contains sequence mutations in chemokine receptors that is conserved for G-
protein coupling. To examine this hypothesis, siRNA interference studies along 
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with Gai inhibitor pertussis toxin and G~ protein I Gy protein inhibitor U-73122 
were also used. 
My results showed that siRNA directed against CXCR7 alone down-
regulated its mRNA expression for both MCF-7 and MDA-MB-231 celis. When a 
combination of siRNA CXCR4 + pertussis toxin or U-73122 was used, only in the 
presence of pertussis toxin was CXCR7 mRNA significantly inhibited but for U-
73122 there was no change. This suggests that CXCR7 cell signaling must 
involve a pathway independent of its G-protein or Gai pertussis toxin sensitive. 
However, since it has been established that CXCR7 activation leads to no 
calcium flux (123,124), a pathway independent of its G-protein would be more 
logical. Moreover, CXCL 12 engagement with CXCR7 can transmit a range of 
cellular responses, such as activation of ERK1/2 and Akt pathways, receptor 
internalization, cell survival, proliferation, adhesion, and chemotaxis of CXCR4-
negative cells (125-128). Hence, CXCL 12 does not behave as a neutral ligand 
for CXCR7; instead, CXCR7 may sequester CXCL 12 thereby modifying the 
chemokine ligand concentration in the extracellular environment. This process is 
key for cell migration (126). 
Here, I also demonstrated that siRNA against CXCR4 down-regulated its 
mRNA expression by both MCF-7 and MDA-MB-231 celis, but in the presence of 
CXCR7 siRNA plus U-73122 there was an up-regulation of CXCR4 mRNA. Two 
key events may account for this finding. First, this particular G~ protein I Gy 
protein inhibitor has been shown to be effective against these subunits, but it has 
no effect on calcium and cAMP production. Indeed, Ca2+ flux and cAMP can act 
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as intracellular second messengers towards increasing CXCR4 transcription 
(129) via PKCt;. Second, receptor hetero/homodimer formation in BrCa cells that 
co-express both receptors. To this end, chemokine receptors can "crosstalk" or 
signal from one receptor to another via heterodimers so that one promoter can 
modify the function of the other through trans-conformational changes (130). 
Therefore, it can be hypothesized that CXCR7 can differentially mediate CXCR4 
functions in heterodimer formation through allosteric interactions. This 
phenomenon has been reported for other chemokine receptors that signal when 
engaged as heterodimer pairs (131). Conformational changes within CXCR4/Gai 
protein complexes in the presence of CXCR7 may represent a molecular 
mechanism for altering G protein-dependent signaling downstream of 
CXCR4/CXCR7 heterodimers. In addition to this, pharmacological interference 
alone may not be sufficient for inhibiting cell signaling events down-stream of the 
heterodimer. Therefore, siRNA interference is a more efficient way to inhibit 
CXCR4 and CXCR7 gene expression and alter breast cancer cell metastasis. 
CXCL 12 plays a major role in BrCa cell metastasis due to its 
chemoattractant property via CXCR4. The density of CXCR4 on BrCa cells is 
proportional to the invasiveness of the cancer (132). Furthermore, the 
expression of CXCR7 by BrCa cells enhances cell growth, survival, and adhesion 
properties. I sought to determine CXCL 12 mRNA expression in the presence of 
siRNA plus pertussis toxin and/or U-73122 and its stimulatory effect on MCF-7 
and MDA-MB-231 cell lines. Semi-quantitative RT-PCR demonstrated that in the 
presence of siRNA against CXCR4 or CXCR7 as well as U-73122, CXCL 12 
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mRNA expression was up regulated (MCF-7); however, its mRNA was 
completely abrogated in MDA-MB-231 cells for the same treatments. When both 
receptors were knockdown and in the presence of pertussis toxin, there was 
complete abrogation of CXCL 12 mRNA. These findings correlate with earlier 
findings that demonstrated siRNA interference of CXCR4 inhibits BrCa 
metastasis. The least aggressive BrCa cell line, MCF-7, expressed 1.5 fold 
higher CXCL 12 mRNA after CXCL 12 protein stimulation than similarly treated 
MDA-MB-231 cells. This finding is also consist with a study from Wendt et a/., 
showing that BrCa cells can undergo epigenetic silencing of CXCL 12, which 
results in increased metastasis as well as CXCR4 mRNA expression. They also 
noted that several Sp1-binding sites are critical for CXCL 12 promoter activity 
when heavily methylated in cells lacking marked CXCL 12 expression, i.e., MDA-
MB-231. However, when these cells were re-established with endogenous 
CXCL 12, there was hyper-responsiveness to exogenous CXCL 12, which 
contributed to increased metastatic potential of these BrCa cells independent of 
CXCR4 expression regulation (133). My results are consistent with this previous 
observation, since CXCR4 inhibition resulted increased CXCL 12 mRNA 
expression. 
When MCF-7 and MDA-MB-231 cell lines were stimulated with CXCL 12, 
both CXCR4 and CXCR7 translocated to the majority of cell nuclei. Similarly, 
advance breast tumors also displayed more CXCR7 protein expression in nuclei 
than cytoplasm. This is a significant finding because only a select few of GPCRs 
can translocate from the cell membrane to the nucleus. 
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For the first time, I demonstrated CXCR4 and CXCR7 expression levels 
vary with cell cycle. Both CXCR4 and CXCR7 expression were the highest in 
cell cycle phase G2. HMECs showed a similar pattern of CXCR4 and CXCR7 
expression during various phases of the cell cycle. These findings suggest that 
expression of these chemokine receptors correlates with cell cycle phases to 
possibly support cell proliferation. Indeed, crosstalk between CXCR7 and 
CXCR4 is involved in up-regulating genes, i.e. Cyclin B, Cyclin A, Cdc29, that 
are needed for cell cycle progression as well as down-regulating the activity of 
p53 (134) (Figure 29). 
Neoplastic epithelial cells engage in reciprocal molecular dialogue with 
surrounding stromal cells, including inflammatory cells, vascular cells, and 
fibroblasts which results in the production of stromal-derived tumor aiding factors 
e.g., growth factors, chemokines, cytokines, proteases, and vascular-stimulating 
factors (135). BrCa represents a carcinoma in which collaborative efforts from 
malignant epithelial cells and stromal cells within the primary tumor coordinate 
carcinogenesis and ultimately metastasis to distant organs (136). In this regard, 
BrCa cells must penetrate the basement membrane and invade the interstitial 
stroma to initiate the metastatic process. Many proteinases are capable of 
degrading the extracellular matrix components but matrix metalloproteinases 
(MMPs) appear to be particularly important for matrix degradation/remodeling 
and cancer cell dissemination (64, 65). Furthermore, abnormal production of 
these proteinases is implicated in a number of pathological conditions (66). 
Collagenases (MMP-1 and -13) degrade several native fibril collagens, including 
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Figure 29. Cyclins, cell cycle regulators, and genes possibly mediated by 
CXCR4 and CXCR7 cross-talk following CXCL 12 stimulation. Crosstalk 
between CXCR4 and CXCR7 has been shown to regulate cell cycle cyclins i.e., 
Cyclin A (8, G2 , and M phase) , Cyclin B (G2 phase) as well as cell cycle 
regulators E2F and p53. These cell cycle components are critical factors for cell 
proliferation and survival during breast cancer progression. 
76 
types I, II and III, which result in their cleavage. 
In this study, I demonstrated BrCa cells express moderate to low levels of 
MMP-1 and MMP-13. After CXCL 12 stimulation, there was an up-regulation of 
MMP-1 and a down-regulation of MMP-13 mRNA expression respectively. For 
MCF-7 cells there was no change in either MMP mRNA expression after 
CXCL 12 stimulation. In normal physiology, the basal expression of most MMPs, 
including MMP-1 and -13, is low. Other investigators have shown that MMPs 
are over-expressed in BrCa and play important roles in cell invasion and 
metastasis (137). Furthermore, the up-regulation of MMP-1 mRNA does 
inversely correlate with ER status as shown here concerning MDA-MB-231 cells. 
It has been demonstrated that as the presence of estrogen receptor predicts a 
low risk of relapse and good overall survival, MMP-1 mRNA up-regulation is a 
potential reason for poor outcome of patients with ER-negative breast cancers 
(138). Increased MMP-1 protein expression has been associated with 
malignancy or invasiveness of breast cancer. siRNA interference against both 
receptors altered MMP-1 and -13 induction. This variance is a result of related, 
yet different induction pathways. 
Studies have demonstrated that MMP-13 induction requires p38 mitogen-
activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) activation as 
well as NF-kB translocation (139). In contrast, MMP-1 induction involves p38 
MAPK and MAPK of the extracellular signal-regulated kinase (MEK) activation, 
but not JNK activation or NF-kB translocation. While p38 MAPK and MEK 
activity is increased by CXCL 12 stimulation of hematopoietic progenitor and 
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lymphocytes, JNK is not activated by this chemokine (140,141). The modulation 
of NF-kB translocation by CXCL 12 is not as certain, but my data suggest that 
CXCL 12 stimulation can simultaneously increase p38 MAPK and MEK activity, 
while lowering and/or not affecting JNK activity or NF-kB translocation which 
would presumably lead to higher increases in MMP-1 expression when 
compared to MMP-13. Here, CXCL 12 induction through CXCR4 and/or CXCR7, 
increased MMP-1 mRNA and protein expression by MCF-7 and MDA-MB-231 
cell lines. siRNA against CXCR4 and/or CXCR7 along with Gai inhibitor 
pertussis toxin was able to inhibit this induction. The G~ protein /Gy protein 
inhibitor U-73122 selectively inhibited MMP-1 induction. These findings highlight 
the significance of MMP gene expression regulated at the transcriptional level by 
CXCL 12-CXCR4/CXCR7 interactions. 
MMP promoters harbor cis-elements allowing for the regulation of MMP 
gene expression by a diverse set of trans-activators including AP-1, PEA3, Sp-1, 
~-catenin/Tcf-4, and NF-kB (142). It is possible that restricted BrCa cell-type 
expression of transcriptional factors is needed for optimal MMP induction. 
Notwithstanding, the mechanism(s) governing BrCa tissue/cell-type specific MMP 
expression are poorly understood. However, it can be postulated that BrCa cell 
growth without motility, i.e. epithelial cell growth, is supported by MMP-1 but not 
MMP-13, while tumor cell motility and invasion requires selective MMP-1 and 
MMP-13 activity. 
CXCL 12 and its receptors CXCR4 and CXCR7 have recently sparked 
substantial interest because of their role in tumorigenesis including tumor growth, 
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invasion, and metastasis (114, 143). This chemokine and its receptors are able 
to mediate multiple signal transduction pathways and a variety of cellular 
functions such as cell migration, proliferation, and survival. Unfortunately, there 
are few studies linking the cellular functions and individual signaling pathways 
mediated by CXCL 12, CXCR4, and CXCR7 interactions with BrCa cells. In this 
study, I show for the first time that HMECs express phosphorylated or active NF-
kB and ERK1/2 in the cytosol. Further, MCF-7 and MDA-MB-231 cells express 
significant pools of activated NF-kB and ERK1/2 within the cytosol. 
CXCR4 is a Gai-protein coupled receptor and studies have shown that 
upon high affinity binding of CXCL 12, it causes mobilization of calcium, decrease 
of cyclic AMP within the cells, and activation of multiple signaling pathways. 
These pathways include: PI3K, phospholipase C-y/protein kinase C, and MAP 
kinases ERK1/2 (144). I hypothesized that CXCR7 cell signaling involved a G 
protein-independent pathway, which depended on its association with JAT/STAT 
through PI3K activation and the induction of downstream signaling mediators 
AKT/NF-kB and RAS/Raf/MEKlERK1/2. However, nearly all previous studies 
concerning these molecules were performed using leukocytes or stem cells 
(145). Due to the important roles of CXCR4/CXCL 12 in BrCa cell metastasis, I 
investigated CXCL 12/CXCR4/CXCR7 regulated cell signaling in BrCa cells. For 
this purpose, MCF-7 and MDA-MB-231 cell lines were treated with CXCL 12 and 
analyzed for changes in active ERK1/2 and NF-kB translocation to the nucleus. 
Further, CXCL 12 stimulation lead to the activation of ERK1/2 and NF-kBp65 in 
BrCa cells. Similarity indexes and image analyses for protein expression also 
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showed significant translocation of ERK1/2 and NF-kB to the nucleus of cells 
(~90% of the cells stained positive for ERK1/2 phosphorylation at residues T202 
and Y204 and NF-kBp65 phosphorylation at residue S529). 
These findings correlate with other studies that showed ERK1/2 directly 
phosphorylates many transcriptional factors including Ets-1, c-Jun and c-myc that 
are important for BrCa progression (146). Active ERK1/2 can enter the nucleus 
itself and phosphorylate many transcription factors and proteins involved in cell 
cycle regulation (146). Others have demonstrated that through an indirect 
mechanism, ERK1/2 can activate NF-kB through phosphorylation of IKK (147). 
Active NF-kB translocation to the nucleus is key for the promotion of NF-kBp65-
dependent transcription (148). Crosstalk between the CXCL 12-CXCR4/CXCR7 
most likely induces RAS/Raf/MEKlERK1/2 and PI3K1AKT pathways for cell 
survival and/or phosphorylation of BAD and caspase-9 to suppress apoptosis. 
These pathways have diverse effects that could regulate cell cycle progression, 
apoptosis and differentiation of BrCa cells (148). 
CXCL 12-CXCR4/CXCR7 cell signaling is a very complex network. 
CXCR4 and CXCR7 siRNA interference lead to a decrease in ERK1/2 and NF-
kB activation and translocation in BrCa cells. Further, pertussis toxin, which 
inhibits both Gai protein-dependent and G protein-independent signaling, lead to 
suppression of both CXCR4 and CXCR7 activation and translocation after 
CXCL 12 stimulation. U-73122 was able to modulate the functional response of 
CXCR4, CXCR7, ERK1/2 and NF-kB presumably due to GP protein / Gy protein 
inhibition, but it has no effect on calcium or cAMP production. When siRNA was 
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used to inhibit CXCR7 expression, CXCL 12 stimulatoin failed to induce ERK1/2 
or NF-kB nucleus translocation. Hence, ERK1/2 and NF-kB activation is 
dependent on PI3K induction and other G protein-dependent events (144). Taken 
together, this dissertation supports that CXCL 12/CXCR4/CXCR7 interactions are 





This study directly investigated the hypothesis that CXCR7 and its 
interactions with CXCR4 and CXCL 12 promote BrCa cell collagenase 
expression, alter NF-KB and ERK1/2 localization to the nucleus, and correlates 
with cell cycle. The experiments detailed in this study determined mRNA and 
protein expression of CXCR7 and CXCR4 along with their functional responses 
to their ligand, CXCL 12. It was demonstrated that primary mammary epithelial 
cells and MCF-7 and MDA-MB-231 cell lines express CXCR4 and CXCR7 mRNA 
as well as protein. 
The overall purpose of this study was to yield significant and substantive 
results that would reveal new insights into the role of this chemokine and its 
receptors involved in BrCa cell progression. Further, to determine what cell 
signaling pathways i.e. RAS/Raf/MEKlERK1/2; AKT/NF-kB may be involved in 
CXCR7/CXCR4 and CXCL 12 interactions as well as the ability of siRNA 
interference along with the Gai protein inhibitor, pertussis toxin, and the G~ 
protein I Gy protein inhibitor, U-73122, to mitigate BrCa cell progression. I also 
conclude that primary breast epithelial and cancer cells express significant pools 
of active NF-kBp65 and ERK1/2 in the cytosol. After CXCL 12 stimulation and 
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activation of CXCR4/CXCR7, these multiple cell signaling components 
translocate to cell nuclei. 
It is important to understand whether or not CXCR7 is able to signal via a 
G protein-independent pathway. Here, I postulated that this receptor was able to 
signal via the association of JAKISTAT with its C-terminal tail upon GRK 
phosphorylation due to cross-talk after CXCR4-CXCL 12 interactions. Related 
studies have indicated that CXCR7 cell signaling pathways involve no Significant 
Ca2+ flux or cell migration; perhaps through heterodimer interactions with 
CXCR4, CXCR7 is able to mitigate cell migration, invasion and survival. 
Chemokine receptor heterodimers can signal just as efficiently as homodimers; 
moreover, receptor number and expression is dependent on specific cell-types 
and/or involves translation as well as post-translational modifications for receptor 
function. Further studies will be needed to determine if these ideas hold true. 
Lastly, chemokines and their receptors are able to mediate other biological 
activities besides cancer cell migration, invasion and survival. These interactions 
may represent major obstacles for therapeutic strategies. However, deciphering 
signaling pathways activated by chemokines in various cancer cells will be critical 
towards understanding how chemokines influence disease progression and may 
reveal potential downstream therapeutic targets. 
83 
REFERENCES 
1. O'Hayre, M., C. Salanga, T. Handel, and S. Allen. 2008. Chemokines and 
Cancer: Migration, Intracellular Signaling and Intercellular Communication 
in the Microenvironment. Biochemical Journal 409:635-649. 
2. Schedin, P., and A. Elias. 2004. Multistep Tumorigenesis and The 
Microenvironment. Breast Cancer Research 6:93-101. 
3. Sporn, M., and N. Suh. 2002. Chemoprevention: An Essential Approach to 
Controlling Cancer. Nat Rev Cancer 2:537-543. 
4. Ramaswamy, S., K. Ross, E. Lander, and T. Golub. 2003. A Molecular 
Signature of Metastasis in Primary Solid Tumors. Nat Genet 33:49- 54. 
5. Bernards, R., and R. Weinberg. 2002. A Progression Puzzle. Nature 
418:823. 
6. Fearon, E., and B. Vogelstein. 1990. A Genetic Model for Colorectal 
Tumorigenesis. Cell 61 :759-767. 
7. Debnath, J., K. Mills, N. Collins, M. Reginato, S. Muthuswamy, and J. 
Brugge. 2002. The Role of Apoptosis in Creating and Maintaining Luminal 
Space Within Normal and Oncogene-Expressing Mammary Acini. Cell 
111 :29-40. 
8. Weaver, V., O. Petersen, F. Wang, C. Larabell, P. Briand, C. Damsky, and 
M. Bissell. 1997. Reversion of the Malignant Phenotype of Human Breast 
Cells in Three-Dimensional Culture and In Vivo by Integrin Blocking 
Antibodies. J Cell Bioi 137:231-245. 
9. Chauhan, H., A. Abraham, J. Phillips, J. Pringle, R. Walker, and J. Jones. 
2003. There is More Than One Kind of Myofibroblasts: Analysis of CD34 
84 
Expression in Benign, In Situ, and Invasive Breast Lesions. J Clin Pathol 
56:271-276. 
10. Tuxhorn, J., G. Ayala, M. Smith, V. Smith, T. Dang, and D. Rowley. 2002. 
Reactive Stroma in Human Prostate Cancer: Induction of Myofibroblasts 
Phenotype and Extracellular Matrix Remodeling. Clin Cancer Research 
8:2912-2923. 
11. Orimo, A, P. Gupta, D. Sgroi, F. Arenzana-Seisdedos, T. Delaunay, R. 
Naeem, V. Carey, A Richardson, and R. Weinberg. 2005. Stromal 
Fibroblasts Present in Invasive Human Breast Carcinoma Promote 
Tumour Growth and Angiogenesis Through Elevated SDF-1/CXCL 12 
Secretion. Cell 121 :335-348. 
12. Silzle, T., M. Kreutz, M. Dobler, G. Brockhoff, R. Knuechel, and L. Kunz-
Schughart. 2003. Tumour Associated Fibroblasts Recruit Blood 
Monocytes into Tumour Tissue. Eur. J of Immunology 33:1311-1320. 
13. Vandercappellen, J., J. Van Damme, and S. Struyf. 2008. The Role of 
CXC Chemokines and Their Receptors in Cancer. Cancer Letter 267:226-
244. 
14. Zlotnik, A, and O. Yoshie. 2000. Chemokines: a new classification system 
and their role in immunity. Immunity 12:121-127. 
15. Murphy, P., M. Baggiolini, I. Charo, C. Hebert, R. Horuk, K. Matsushima, 
L. Miller, J. Oppenheim, and C. Power. 2000. Nomenclature for 
Chemokine Receptors. Pharmacology Review 1: 145-176. 
16. Balkwill, F. 2004. Cancer and the Chemokine Network. Nat Rev Cancer 
7:540-550. 
17. Campbell, J. J., and E. C. Butcher. 2000. Chemokines in tissue-specific 
and microenvironment-specific lymphocyte homing. Current Opinion in 
Immunology 12:336-341. 
18. Butcher, E. C., M. Willima, K. Youngman, L. Rott, and M. Briskin. 1999. 
Lymphocyte trafficking and regional immunity. Advances in Immunology 
72:209-253. 
85 
19. Muller, A., B. Homey, H. Soto, N. Ge, D. Catron, M. E. Buchanan, T. 
McClanahan, E. Murphy, W. Yuan, S. N. Wagner, J. L. Barrera, A. Mohar, 
E. Verastegui, and A. Zlotnik. 2001. Involvement of chemokine receptors 
in breast cancer metastasis.[comment]. Nature. 410:50-56. 
20. Gupta, G., and J. Massague. 2006. Cancer Metastasis: Building a 
Framework. Cell 127:679-695. 
21. Ben-Baruch, A. 2003. Host Microenvironment in Breast Cancer 
Development: Inflammatory Cells, Cytokines, and Chemokines in Breast 
Cancer Progression: Reciprocal Tumour-Microenvironment Interactions. 
Breast Cancer Research 5:31-36. 
22. Kulbe, H., N. Levinson, F. Balkwill, and J. Wilson. 2004. The Chemokine 
Network- Much More Than Directing Cell Movement. Int. J Oev. Biology 
48:489-496. 
23. Balkwill, F. 2004. The significance of cancer cell expression of the 
chemokine receptor CXCR4. Seminars in Cancer Biology 14:171-179. 
24. Shirozu, M., T. Nakano, J. Inazawa, K. Tashiro, H. Tada, T. Shinohara, 
and T. Honjo. 1995. Structure and Chromosomal Localization of the 
Human Stromal Cell-Derived Factor 1. Genomics 374:174-179. 
25. Hesselgesser, J., M. Liang, J. Hoxie, M. Greenberg, L. Brass, M. Orsini, 
D. Taub, and R. Horuk. 1998. Identification and Characterization of the 
CXCR4 Chemokine Receptor in Human T-Cell Lines. Gene 2:877-883. 
26. Feng, Y., C. C. Broder, P. E. Kennedy, and E. A. Berger. 1996. HIV-1 
entry cofactor: functional cDNA cloning of a seven-transmembrane, G 
protein-coupled receptor.[see comment]. Science 272:872-877. 
27. Zlotnik, A. 2006. Involvement of Chemokine Receptors in Organ-specific 
Metastasis. Contrib Microbio/13:191-199. 
28. Koshiba, T., R. Hosotani, Y. Miyamoto, J. Ida, S. Tsuji, S. Nakajima, M. 
Kawaguchi, H. Kobayashi, R. Doi, T. Hori, N. Fujii, and M. Imamura. 2000. 
Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor 
system in pancreatic cancer: a possible role for tumor progression. Clinical 
Cancer Research. 6:3530-3535. 
86 
29. Scotton, C. J., J. L. Wilson, D. Milliken, G. Stamp, and F. R. Balkwill. 
2001. Epithelial cancer cell migration: a role for chemokine receptors? 
Cancer Research. 61 :4961-4965. 
30. Marchese, A., and J. Benovic. 2001. Agonist-Promoted Ubiquitination of 
The G Protein-Coupled Receptor CXCR4 Mediates Lysosomal Sorting. J 
BioI Chem 49:45509-45512. 
31. Li, Y. M., Y. Pan, Y. Wei, X. Cheng, B. P. Zhou, M. Tan, X. Zhou, W. Xia, 
G. N. Hortobagyi, D. Yu, and M. C. Hung. 2004. Upregulation of CXCR4 is 
essential for HER2-mediated tumor metastasis.[see comment]. Cancer 
Cell 6:459-469. 
32. Zhang, G. J., and I. Adachi. 1999. Serum interleukin-6 levels correlate to 
tumor progression and prognosis in metastatic breast carcinoma. 
Anticancer Research 19:1427-1432. 
33. Kang, H., G. Watkins, C. Parr, A. Douglas-Jones, R. E. Mansel, and W. G. 
Jiang. 2005. Stromal cell derived factor-1: its influence on invasiveness 
and migration of breast cancer cells in vitro, and its association with 
prognosis and survival in human breast cancer. Breast Cancer Research 
7:R402-410. 
34. Proost, P., A. Mortier, T. Loos, J. Vandercappellen, M. Gouwy, I. Ronsse, 
E. Schutyser, W. Put, M. Parmentier, S. Struyf, and J. Van Damme. 2007. 
Proteolytic processing of CXCL 11 by CD13/aminopeptidase N impairs 
CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and 
endothelial cell migration. Blood 110:37-44. 
35. Cannistra, S. A., and J. D. Griffin. 1988. Regulation of the production and 
function of granulocytes and monocytes. Seminars in Hematology25:173-
188. 
36. Hillyer, P., E. Mordelet, G. Flynn, and D. Male. 2003. Chemokines, 
chemokine receptors and adhesion molecules on different human 
endothelia: discriminating the tissue-specific functions that affect leucocyte 
migration. Clinical & Experimental Immunology 134:431-441. 
37. Cooper, C. R., J. K. Bhatia, H. J. Muenchen, L. McLean, S. Hayasaka, J. 
Taylor, P. J. Poncza, and K. J. Pienta. 2002. The regulation of prostate 
cancer cell adhesion to human bone marrow endothelial cell monolayers 
87 
by androgen dihydrotestosterone and cytokines. Clinical & Experimental 
Metastasis 19:25-33. 
38. Jung, Y., J. Wang, A. Schneider, Y. X. Sun, A. J. Koh-Paige, N. I. Osman, 
L. K. McCauley, and R. S. Taichman. 2006. Regulation of SDF-1 
(CXCL 12) production by osteoblasts; a possible mechanism for stem cell 
homing. Bone 38:497-508. 
39. Knaut, H., C. Werz, R. Geisler, C. Nusslein-Volhard, and C. Tubingen 
Screen. 2003. A zebrafish homologue of the chemokine receptor Cxcr4 is 
a germ-cell guidance receptor.[see comment]. Nature 421 :279-282. 
40. Dambly-Chaudiere, C., N. Cubedo, and A. Ghysen. 2007. Control of cell 
migration in the development of the posterior lateral line: antagonistic 
interactions between the chemokine receptors CXCR4 and CXCR7/RDC1. 
BMC Developmental Biology 7:23. 
41. Valentin, G., P. Haas, and D. Gilmour. 2007. The chemokine SDF1 a 
coordinates tissue migration through the spatially restricted activation of 
Cxcr7 and Cxcr4b. Current Biology 17: 1026-1031 . 
42. Thelen, M., and S. Thelen. 2008. CXCR7, CXCR4 and CXCL 12: An 
Eccentric Trio? Journal of Neuroimmunology.1-5. 
43. Schonemeier, B., S. Schulz, V. Hoellt, and R. Stumm. 2008. Enhanced 
Expression of the CXCL 12/SDF-1 Chemokine Receptor CXCR7 After 
Cerebral Ischemia in the Rat Brain. Journal of Neuroimmunology.1-7. 
44. Burns, J. M., B. C. Summers, Y. Wang, A. Melikian, R. Berahovich, Z. 
Miao, M. E. T. Penfold, M. J. Sunshine, D. R. Littman, C. J. Kuo, K. Wei, 
B. E. McMaster, K. Wright, M. C. Howard, and T. J. Schall. 2006. A novel 
chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell 
adhesion, and tumor development. Journal of Experimental Medicine 
203:2201-2213. 
45. Levoye, A., K. Balabanian, F. Baleux, F. Bachelerie, and B. Lagane. 2009. 
CXCR7 Heterodimerizes with CXCR4 and Regulates CXCL 12-Mediated G 
Protein Signaling. Blood 113:6085-6093. 
88 
46. Grabovsky, V., S. Feigelson, C. Chen, D. A. Bleijs, A. Peled, G. Cinamon, 
F. Baleux, F. Arenzana-Seisdedos, T. Lapidot, Y. van Kooyk, R. R. Lobb, 
and R. Alon. 2000. Subsecond induction of alpha4 integrin clustering by 
immobilized chemokines stimulates leukocyte tethering and rolling on 
endothelial vascular cell adhesion molecule 1 under flow conditions. 
Journal of Experimental Medicine 192:495-506. 
47. Taub, D. D., A. R. Lloyd, K. Conlon, J. M. Wang, J. R. Ortaldo, A. Harada, 
K. Matsushima, D. J. Kelvin, and J. J. Oppenheim. 1993. Recombinant 
human interferon-inducible protein 10 is a chemoattractant for human 
monocytes and T lymphocytes and promotes T cell adhesion to 
endothelial cells. Journal of Experimental Medicine 177: 1809-1814. 
48. Taub, D. D., K. Conlon, A. R. Lloyd, J. J. Oppenheim, and D. J. Kelvin. 
1993. Preferential migration of activated CD4+ and CD8+ T cells in 
response to MIP-1 alpha and MIP-1 beta. Science 260:355-358. 
49. Tanaka, Y., D. H. Adams, S. Hubscher, H. Hirano, U. Siebenlist, and S. 
Shaw. 1993. T-cell adhesion induced by proteoglycan-immobilized 
cytokine MIP-1 beta. Nature. 361 :79-82. 
50. Weber, C., C. F. Lu, J. M. Casasnovas, and T. A. Springer. 1997. Role Of 
Alpha(L)Beta(2) Integrin Avidity In Transendothelial Chemotaxis Of 
Mononuclear Cells. Journal of Immunology 159:3968-3975. 
51. Weber, C., R. Alon, B. Moser, and T. A. Springer. 1996. Sequential 
regulation of alpha 4 beta 1 and alpha 5 beta 1 integrin avidity by CC 
chemokines in monocytes: implications for transendothelial chemotaxis. 
Journal of Cell Biology 134: 1063-1073. 
52. Mauro, L., D. Sisci, M. Bartucci, M. Salerno, J. Kim, T. Tam, M. A. 
Guvakova, S. Ando, and E. Surmacz. 1999. SHC-alpha5beta 1 integrin 
interactions regulate breast cancer cell adhesion and motility. 
Experimental Cell Research 252:439-448. 
53. Vellon, L., J. A. Menendez, and R. Lupu. 2006. A bidirectional 
"alpha(v)beta(3) integrin-ERK1/ERK2 MAPK" connection regulates the 
proliferation of breast cancer cells. Molecular Carcinogenesis 45:795-804. 
54. Gasparini, G., P. C. Brooks, E. Biganzoli, P. B. Vermeulen, E. Bonoldi, L. 
Y. Dirix, G. Ranieri, R. Miceli, and D. A. Cheresh. 1998. Vascular integrin 
89 
alpha(v)beta3: a new prognostic indicator in breast cancer. Clinical Cancer 
Research 4:2625-2634. 
55. Vellon, L., J. A. Menendez, and R. Lupu. 2005. AiphaVbeta3 integrin 
regulates heregulin (HRG)-induced cell proliferation and survival in breast 
cancer. Oncogene 24:3759-3773. 
56. Spangenberg, C., E. U. Lausch, T. M. Trost, D. Prawitt, A. May, R. 
Keppler, S. A. Fees, D. Reutzel, C. Bell, S. Schmitt, I. B. Schiffer, A. 
Weber, W. Brenner, M. Hermes, U. Sahin, O. Tureci, H. Koelbl, J. G. 
Hengstler, and B. U. Zabel. 2006. ERBB2-mediated transcriptional up-
regulation of the alpha5beta 1 integrin fibronectin receptor promotes tumor 
cell survival under adverse conditions. Cancer Research 66:3715-3725. 
57. Langsenlehner, U., W. Renner, B. Yazdani-Biuki, T. Eder, T. C. Wascher, 
B. Paulweber, H. Clar, G. Hofmann, H. Samonigg, and P. Krippl. 2006. 
Integrin alpha-2 and beta-3 gene polymorphisms and breast cancer risk. 
Breast Cancer Research & Treatment 97:67-72. 
58. Mahabeleshwar, G. H., W. Feng, K. Reddy, E. F. Plow, and T. V. Byzova. 
2007. Mechanisms of integrin-vascular endothelial growth factor receptor 
cross-activation in angiogenesis.[see comment]. Circulation Research 
101 :570-580. 
59. Corbett, S. A., and J. E. Schwarzbauer. 1999. Beta3 integrin activation 
improves alphavbeta3-mediated retraction of fibrin matrices. Journal of 
Surgical Research 83:27-31 . 
60. Samara, G., D. Lawrence, C. Chiarelli, M. Valentino, S. Lyubsky, S. 
Zucker, and G. Vaday. 2004. CXCR4-Mediated Adhesion and MMP-9 
Secretion in Head and Neck Squamous Cell Carcinoma. Cancer Letter 
2:231-241. 
61. Wright, N., A. Hidalgo, J. Rodriguez-Frade, S. Soriano, M. Mellado, M. 
Parmo-Cabanas, M. Briskin, and J. Teixido. 2002. The Chemokine 
Stromal Cell-Derived Factor 1 Alpha Modulates Alpha 4 Beta 7 Integrin-
Mediated Lymphocyte Adhesion to Mucosal Addressin Cell Adhesion 
Molecule-1 and Fibronectin. J Immuno/1 0:5268-5277. 
62. Zhao, Y., R. Bachelier, I. Treilleux, P. Pujuguet, O. Peyruchaud, R. Baron, 
P. Clement-Lacroix, and P. Clezardin. 2007. Tumor alphavbeta3 integrin is 
90 
a therapeutic target for breast cancer bone metastases. Cancer Research 
67:5821-5830. 
63. Baum, 0., R. Hlushchuk, A. Forster, R. Greiner, P. Clezardin, Y. Zhao, V. 
Djonov, and G. Gruber. 2007. Increased invasive potential and up-
regulation of MMP-2 in MDA-MB-231 breast cancer cells expressing the 
beta3 integrin subunit. International Journal of Oncology 30:325-332. ' 
64. Nagase, H., and J. F. Woessner, Jr. 1999. Matrix metalloproteinases. 
Journal of Biological Chemistry274:21491-21494. 
65. Hulboy, D. L., L. A. Rudolph, and M. Matrisian. 1997. Matrix 
metalloproteinases as mediators of reproductive function. Molecular 
Human Reproduction. 3:27-45. 
66. Stetler-Stevenson, W. G., S. Aznavoorian, and L. A. Liotta. 1993. Tumor 
cell interactions with the extracellular matrix during invasion and 
metastasis. Annual Review of Cell Biology. 9:541-573. 
67. Balduyck, M., F. Zerimech, V. Gouyer, R. Lemaire, B. Hemon, G. Grard, 
C. Thiebaut, V. Lemaire, E. Dacquembronne, T. Duhem, A. Lebrun, M. J. 
Dejonghe, and G. Huet. 2000. Specific expression of matrix 
metalloproteinases 1, 3, 9 and 13 associated with invasiveness of breast 
cancer cells in vitro. Clinical & Experimental Metastasis 18: 171-178. 
68. Bachmeier, B. E., A. G. Nerlich, R. Lichtinghagen, and C. P. Sommerhoff. 
2001. Matrix metalloproteinases (MMPs) in breast cancer cell lines of 
different tumorigenicity. Anticancer Research 21 :3821-3828. 
69. Hao, L., C. Zhang, Y. Qiu, L. Wang, Y. Luo, M. Jin, Y. Zhang, T. B. Guo, 
K. Matsushima, and Y. Zhang. 2007. Recombination of CXCR4, VEGF, 
and MMP-9 predicting lymph node metastasis in human breast cancer. 
Cancer Letters 253:34-42. 
70. Duffy, M. J., T. M. Maguire, A. Hill, E. McDermott, and N. O'Higgins. 2000. 
Metalloproteinases: role in breast carcinogenesis, invasion and 
metastasis. Breast Cancer Research 2:252-257. 
71. Li, H.-C., D.-C. Cao, Y. Liu, Y.-F. Hou, J. Wu, J.-S. Lu, G.-H. Di, G. Liu, F.-
M. Li, Z.-L. Ou, C. Jie, Z.-Z. Shen, and Z.-M. Shao. 2004. Prognostic value 
91 
of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph 
nOde-negative breast carcinoma. Breast Cancer Research & Treatment 
88:75-85. 
72. Liang, Z., Y. Yoon, J. Votaw, M. M. Goodman, L. Williams, and H. Shim. 
2005. Silencing of CXCR4 blocks breast cancer metastasis. Cancer 
Research 65:967-971. 
73. Miao, Z., K. E. Luker, B. C. Summers, R. Berahovich, M. S. Bhojani, A. 
Rehemtulla, C. G. Kleer, J. J. Essner, A. Nasevicius, G. D. Luker, M. C. 
Howard, and T. J. Schall. 2007. CXCR7 (RDC1) promotes breast and lung 
tumor growth in vivo and is expressed on tumor-associated vasculature. 
Proceedings of the National Academy of Sciences of the United States of 
America 104:15735-15740. 
74. Singh, S., U. P. Singh, W. E. Grizzle, and J. W. Lillard. 2004. CXCL 12-
CXCR4 interactions modulates prostate cancer cell migration, 
metalloproteinase expression and invasion. Laboratory Investigation 
84: 1666-1676. 
75. Etienne-Manneville, S., and A. Hall. 2002. Rho GTPases in cell biology. 
Nature 420:629-635. 
76. Laudanna, C., J. Y. Kim, G. Constantin, and E. Butcher. 2002. Rapid 
leukocyte integrin activation by chemokines. Immunological Reviews 
186:37-46. 
77. Dustin, M. L., T. G. Bivona, and M. R. Philips. 2004. Membranes as messengers 
in T cell adhesion signaling. Nature Immunology 5:363. 
78. Giagulli, c., E. Scarpini, L. Oltoboni, S. Narumiya, E. C. Butcher, G. Constantin, 
and C. Laudanna. 2004. RhoA and zeta PKC control distinct modalities of LFA-
1 activation by chemokines: critical role of LFA-I affinity triggering in 
lymphocyte in vivo homing. Immunity 20:25. 
79. Cantrell, D. A. 2001. Phosphoinositide 3-kinase signalling pathways. 
Journal of Cell Science 114: 1439-1445. 
80. Miyamoto, S., H. Teramoto, J. S. Gutkind, and K. M. Yamada. 1996. 
Integrins can collaborate with growth factors for phosphorylation of 
92 
receptor tyrosine kinases and MAP kinase activation: roles of integrin 
aggregation and occupancy of receptors. Journal of Cell Biology 
135:1633-1642. 
81. Braga, V. 2000. The crossroads between cell-cell adhesion and motility. 
Nature Cell Biology2:E182-184. 
82. lIic, D., Y. Furuta, S. Kanazawa, N. Takeda, K. Sobue, N. Nakatsuji, S. 
Nomura, J. Fujimoto, M. Okada, and T. Yamamoto. 1995. Reduced cell 
motility and enhanced focal adhesion contact formation in cells from FAK-
deficient mice. Nature. 377:539-544. 
83. Fashena, S. J., and S. M. Thomas. 2000. Signalling by adhesion 
receptors. Nature Cell Biology 2:E225-229. 
84. Xue, L., J. H. Murray, and A. M. Tolkovsky. 2000. The 
Ras/phosphatidylinositol 3-kinase and Ras/ERK pathways function as 
independent survival modules each of which inhibits a distinct apoptotic 
signaling pathway in sympathetic neurons. Journal of Biological Chemistry 
275:8817 -8824. 
85. Liotta, L. A., and E. C. Kohn. 1995. Angiogenesis: role of calcium-
mediated signal transduction. Cancer Research 55:1856-1862. 
86. Masiero, L., K. A. Lapidos, I. Ambudkar, and E. C. Kohn. 1999. Regulation 
of the RhoA pathway in human endothelial cell spreading on type IV 
collagen: role of calcium influx. Journal of Cell Science 112:3205-3213. 
87. Nombela-Arrieta, C., R. A. Lacalle, M. C. Montoya, Y. Kunisaki, D. 
Megias, M. Marques, A. C. Carrera, S. Manes, Y. Fukui, A. C. Martinez, 
and J. V. Stein. 2004. Differential requirements for DOCK2 and 
phosphoinositide-3-kinase gamma during T and B lymphocyte homing. 
Immunity 21 :429-441. 
88. Bonaccorsi, L., S. Marchiani, M. Muratori, V. Carloni, G. Forti, and E. 
Baldi. 2004. Singaling mechanisms that mediates invasion in prostate 
cancer cells. Annals of the New York Academy of Sciences 1028:4693. 
89. Shulby, S. A., N. G. Dolloff, M. E. Stearns, O. Meucci, and A. Fatatis. 
2004. CX3CR1-fractalkine expression regulates cellular mechanisms 
93 
involved in adhesion, migration, and survival of human prostate cancer 
cells. Cancer Research 64:4693-4698. 
90. Hendrix, M., E. Seftor, R. Settor, J. Kasemeier-Kulesa, P. Kulesa, and L. 
Postovit. 2007. Reprogramming Metastatic Tumour Cells with Embryonic 
Microenvironments. Nat Rev Cancer 7:246-255. 
91. Nishio, M., T. Endo, N. Tsukada, J. Ohata, S. Kitada, J. Reed, N. Zvaifler, 
and T. Kipps. 2005. Nurselike cells Express BAFF and APRIL, Which Can 
Promote Survival of Chronic Lymphocytic Leukemia Cells via a Paracine 
Pathway Distinct from That of SDF-1 Alpha. Blood 106: 1824-1830. 
92. Balabanian, K., B. Lagane, S. Infantino, K. Y. C. Chow, J. Harriague, B. 
Moepps, F. Arenzana-Seisdedos, M. Thelen, and F. Bachelerie. 2005. 
The chemokine SDF-1/CXCL 12 binds to and signals through the orphan 
receptor RDC1 in T lymphocytes. Journal of Biological Chemistry 
280:35760-35766. 
93. Datta, S. R., A. Brunet, and M. E. Greenberg. 1999. Cellular survival: a 
play in three Akts. Genes & Development 13:2905-2927. 
94. Schuler, M., W. Li, B. Eggers-Sedlet, W. Lee, P. Tailor, P. Fitzgerald, G. 
B. Mills, and D. R. Green. 2001. Linking molecular therapeutics to 
molecular diagnostics: inhibition of the FRAP/RAFTITOR component of 
the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in 
vivo.[comment]. Journal of Biological Chemistry 276:34244-34251. 
95. Balsara, B. R., S. Apostolou, S. C. Jhanwar, and J. R. Testa. 2001. AKT 
plays a central role in tumorigenesis. Proceeding of National Academy 
Science of United States of America 98:10031-10033. 
96. Balsara, B. R., S. Apostolou, S. C. Jhanwar, and J. R. Testa. 2001. AKT 
plays a central role in tumorigenesis.[comment]. Oncogene 20:6245-6249. 
97. Biggs, W. H., 3rd, J. Meisenhelder, T. Hunter, W. K. Cavenee, and K. C. 
Arden. 1999. Protein kinase B/Akt-mediated phosphorylation promotes 
nuclear exclusion of the winged helix transcription factor FKHR1. 
Proceedings of the National Academy of Sciences of the United States of 
America 96:7421-7426. 
94 
98. Allan, L., N. Morrice, S. Brady, G. Magee, S. Pathak, and P. Clarke. 2003. 
Inhibition of Caspase-9 through Phosphorylation at Thr 125 by ERK-
MAPK. Nat Cell Bioi 5:647-654. 
99. Kyriakis, J. 2000. MAP Kinases and the Regulation of Nuclear Receptors. 
Science 48:PE1. 
100. Kerr, J. F., A. H. Wyllie, and A. R. Currie. 1972. Apoptosis: a basic 
biological phenomenon with wide-ranging implications in tissue kinetics. 
British Journal of Cancer 26:239-257. 
101. Denmeade, S. R., and J. T. Isaacs. 1996. Activation of programmed 
(apoptotic) cell death for the treatment of prostate cancer. Advances in 
Pharmacology 35:281-306. 
102. Borner, M. M., C. E. Myers, O. Sartor, V. Sei, T. Toko, J. B. Trepel, and E. 
Schneider. 1995. Drug-induced apoptosis is not necessarily dependent on 
macromolecular synthesis or proliferation in the p53-negative human 
prostate cancer cell line PC-3. Cancer Research 55:2122-2128. 
103. Ve, R. 2001. Regulation of Nuclear Factor -kB Activation by G-Protein 
Coupled Receptors. J Leukocyte Bioi 70:839-848. 
104. Karin, M. 2006. Nuclear Factor -kB in Cancer Development and 
Progression. Nature 441 :431-436. 
105. Lee, B. C., T. H. Lee, S. Avraham, and H. K. Avraham. 2004. Involvement 
of the chemokine receptor CXCR4 and its ligand stromal cell-derived 
factor 1 alpha in breast cancer cell migration through human brain 
microvascular endothelial cells. Molecular Cancer Research: MCR 2:327-
338. 
106. Singh, S., U. P. Singh, J. K. Stiles, W. E. Grizzle, and J. W. Lillard. 2004. 
Expression and Functional Role of CCR9 in Prostate Cancer Cell 
Migration and Invasion. Clinical Cancer Research 10:8743-8750. 
107. Caplen, N., S. Parrish, F. Imani, A. Fire, and R. Morgan. 2001. Specific 
Inhibition of Gene Expression by Small Double-Stranded RNAs in 
Invertebrate and Vertebrate Systems. Nat Biotechnology 98:9742-9747. 
95 
108. Elbashir, S., J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. 
Tuschl. 2001. Duplexes of 21-nucleotide RNAs Mediate RNA Interference 
in Cultured Mammalian Cells. Nature 411 :494-498. 
109. Huang, Y.-C., Y.-C. Hsiao, Y.-J. Chen, Y.-Y. Wei, T.-H. Lai, and C.-H. 
Tang. 2007. Stromal Cell-Derived Factor-1 Enhances Motility and Integrin 
Up-regulation Through CXCR4, ERK and NF-kB-Dependent Pathway in 
Hunman Lung Cancer Cells. Biochemical Pharmacology 74:1702-1712. 
110. Fernandis, A., A. Prasad, H. Band, R. Klosel, and R. Ganju. 2004. 
Regulation of CXCR4-Mediated Chemotaxis and Chemoinvasion of Breast 
Cancer Cells. Oncogene 23:157-167. 
111. Boukerche, H., Z. Su, L. Emdad, D. Sarkar, and P. Fisher. 2007. Mda-
9/Syntenin Regulates the Metastatic Phenotype in Human Melanoma 
Cells By Activating Nuclear Factor-kappa B. Cancer Research 67:1812-
1822. 
112. Nagase, H. 1997. Activation mechanisms of matrix metalloproteinases. 
Biological Chemistry 378: 151-160. 
113. Eck, S., A. Cote, W. Winkelman, and C. Brinckerhoff. 2009. CXCR4 and 
Matrix Metalloproteinase-1 Are Elevated in Breast Carcinoma- Associated 
Fibroblasts and in Normal Mammary Fibroblasts Exposed to Factors 
Secreted by Breast Cancer Cells. Mol Cancer Res 7: 1033-1044. 
114. Muller, A., B. Homey, H. Soto, N. Ge, D. Catron, M. E. Buchanan, T. 
McClanahan, E. Murphy, W. Yuan, S. N. Wagner, J. L. Barrera, A. Mohar, 
E. Verastegui, and A. Zlotnik. 2001. Involvement of chemokine receptors 
in breast cancer metastasis.[see comment]. Nature 41 0:50-56. 
115. Jemal, A., T. Murray, E. Ward, A. Samuels, R. C. Tiwari, A. Ghafoor, E. J. 
Feuer, and M. J. Thun. 2005. Cancer statistic. CA CancerJ Clin 55:10-30. 
116. Luster, A., and A. Viola. 2008. Chemokines and Their Receptors: Drug 
Targets in Immunity and Inflammation. Annual Review of Pharmacology 
and Toxicology48:171-197. 
117. Fidler, U. 2003. The Pathogenesis of Cancer Metastasis: The Seed and 
Soil Hypothesis Revisited. Nat Rev Cancer 3:453-458. 
96 
118. Bissell, M., and D. Radisky. 2001. Putting Tumours In context. Nat Rev 
Cancer 1 :46-54. 
119. Goetzl, E. 2007. Diverse Pathways for Nuclear Signaling by G Protein-
coupled Receptors and Their Ligands. FASEB Journal 21 :638-642. 
120. Hartmann, T., V. Grabovsky, R. Pasvolsky, Z. Shulman, E. Buss, A. 
Spiegel, A. Nagler, T. Lapidot, M. Thelen, and R. Alon. 2008. A Crosstalk 
Between Intracellular CXCR7 and CXCR4 Involved in Rapid CXCL 12-
Triggered Integrin Activation but Not in Chemokine-Triggered Motility of 
Human T Lymphocytes and CD34+ Cells. J of Leukocyte Biology 84: 1130-
1140. 
121. Gales, C., J. Van Durm, and S. Schaak. 2006. Probing the Activation-
Promoted Structural Rearrangements in Preassembled Receptor-G 
Protein Complexes. Nat Struct Mol Bioi 13:778-786. 
122. Audet, N., C. Gales, and E. Archer-Lahlou. 2008. Bioluminescence 
Resonance Energy Transfer Assays Reveal Ligand-Specific 
Conformational Changes Within Preformed Signaling Complexes 
Containing Delta-Opioid Receptors and Heterotrimeric G Proteins. J Bioi 
Chern 283:15078-15088. 
123. Infantino, S., B. Moepps, and M. Thelen. 2006. Expression and Regulation 
of the Orphan Receptor RDC1 and Its Putative Ligand in Human Dendritic 
and B Cells. J Irnrnuno/176:2197-2207. 
124. Sierro, F., C. Biben, and L. Martinez-Munoz. 2007. Disrupted Cardiac 
Development but Normal Hematopoiesis in Mice Deficient in the Second 
CXCL 12/SDF-1 Receptor CXCR7. Proc Natl Acad Sci USA 104:14759-
14764. 
125. Wang, J., Y. Shiozawa, and J. Wang. 2008. The Role of CXCR7/RDC1 As 
a Chemokine Receptor for CXCL 12-SDF-1 in Prostate Cancer. J Bioi 
Chern 283:4283-4294. 
126. Boldajipour, B., H. Mahabaleshwar, and E. Kardash. 2008. Control of 
Chemokine-Guided Cell Migration By Ligand Sequestration. Cell 132:463-
473. 
97 
127. Meijer, J., J. Ogink, and E. Roos. 2008. Effect of the Chemokine Receptor 
CXCR7 on Proliferation of Carcinoma Cells In Vitro and In Vivo. Breast 
Cancer Research 99: 1493-1501. 
128. Valentin, G., P. Haas, and D. Gilmour. 2007. The Chemokine SDF-1a 
Coordinates Tissue Migration Through the Spatially Restricted Activation 
of CXCR7 and CXCR4b. Curr BioI 17: 1 026-1 031 . 
129. Moriuchi, M., H. Moriuchi, W. Turner, and A. Fauci. 1.997. Cloning and 
Analysis of The Promoter Region of CXCR4, A Coreceptor for HIV-1 
Entry. J Immuno/159:4322-4329. 
130. Pin, J., J. Kniazeff, and J. Liu. 2005. Allosteric Functioning of Dimeric 
Class C G-protein Coupled Receptors. FEBS 272:2947-2955. 
131. Springael, J., E. Urizar, and M. Parmentier. 2005. Dimerization of 
Chemokine Receptors and Its Functional Consequences. Cytokine Growth 
Factor Rev 16:611-623. 
132. Kato, M., J. Kitayama, S. Kazama, and H. Nagawa. 2003. Expression 
pattern of CXC chemokine receptor-4 is correlated with lymph node 
metastasis in human invasive ductal carcinoma. Breast Cancer Research 
5:R144-150. 
133. Wendt, M., A. Cooper, and M. Dwinell. 2008. Epigenetic Silencing of 
CXCL 12 Increases the Metastatic Potential of Mammary Carcinoma Cells. 
Oncogene 27:1461-1471. 
134. Yoshida, D., R. Nomura, and A. Teramoto. 2009. Signaling Pathway 
Mediated by CXCR7, An Alternative Chemokine Receeptor For Stromal 
Cell Derived Factor-1 Alpha in AtT20 Mouse Adrenocorticotrophic 
Hormone-Secreting Pituitary Adenoma Cells. J Neuroendo 21 :481-488. 
135. Mueller, M., and N. Fusenig. 2004. Friends or Foes-Bipolar Effects of the 
Tumour Stroma In Cancer. Nat Rev Cancer 4:839-849. 
136. Parkin, D., F. Bray, J. Ferlay, and P. Pisani. 2002. Global Cancer 
Statistics. CancerJ Clin 55:74-108. 
98 
137. Miyata, Y., T. Iwata, and K. Ohba. 2006. Expression of Matrix 
Metalloproteinase-7 on Cancer Cells and Tissue Endothelial Cells in 
Renal Cell Carcinoma: Prognostic Implications and Clinical Significance 
for Invasion and Metastasis. Clin Cancer Research 12:6998. 
138. Clark, G., and W. McGuire. 1988. Sterooid Receptors and Other 
Prognostic Factors in Primary Breast Cancer. Semin Onco/15:20. 
139. Mengshol, J. A., M. P. Vincenti, C. I. Coon, A. Barchowsky, and C. E. 
Brinckerhoff. 2000. Interleukin-1 induction of collagenase 3 (matrix 
metalloproteinase 13) gene expression in chondrocytes requires p38, c-
Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of 
collagenase 1 and collagenase 3. Arthritis and Rheumatism 43:801-811. 
140. Ganju, R. K., S. A. Brubaker, J. Meyer, P. Dutt, Y. Yang, S. Qin, W. 
Newman, and J. E. Groopman. 1998. The alpha-chemokine, stromal cell-
derived factor-1 alpha, binds to the transmembrane G-protein-coupled 
CXCR-4 receptor and activates multiple signal transduction pathways. 
Journal of Biological Chemistry 273:23169-23175. 
141. Yonezawa, A., T. Hori, and H. Sakaida. 2000. SDF-1 has Costimulatory 
Effects on Human T Cells: Possible Involvement of MAPK (ERK2) 
Activation. Microbiallmmuno/44: 135-141 . 
142. Benbow, U., and C. Brinckerhoff. 1997. The AP-1 Site and MMP Gene 
Regulation: What is All The Fuss About? Matrix bioI 15:519-526. 
143. Taichman, R. S., C. Cooper, E. T. Keller, K. J. Pienta, N. S. Taichman, 
and L. K. McCauley. 2002. Use of the stromal cell-derived factor-1/CXCR4 
pathway in prostate cancer metastasis to bone. Cancer Research. 
62:1832-1837. 
144. Sotsios, Y., G. Whittaker, J. Westwick, and S. Ward. 1999. The CXC 
Chemokine Stromal Cell-Derived Factor Activates a Gi-Coupled 
Phosphoinositide 3-Kinase in T Lymphocytes. J Immuno/163:5954-5963. 
145. Guinamard, R., N. Signoret, and M. ishiai. 1999. B cell Antigen Receptor 
Engagement Inhibits Stromal Cell-Derived Factor SDF-1 Alpha 
Chemotaxis and Promotes Protein Kinase C Induced Internalization of 
CXCR4. Exp Med 189:1461-1466. 
99 
146. Steelman, L., S. Pohnert, J. Shelton, R. Franklin, F. Bertrand, and J. 
McCubrey. 2004. JAKISTAT, Raf/MEKIERK, P13K1Akt and BCR-ABL in 
cell Cycle Progression and Leukemogenesis. Leukemia 18:189-218. 
147. Nakano, H., M. Shindo, S. Sakon, S. Nishinaka, M. Mihara, H. Yagita, and 
K. Okumura. 1998. Differential Regulation of I kappa B Kinase Alpha and 
Beta By Two Upstream Kinases, NF-kB Inducing Kinase and Mitogen 
Activated Protein Kinase ERK Kinase 1. Pro Nat! Acad 95:3537 -3542. 
148. Viatour, P., M. Merville, V. bours, and A. Chariot. 2005. Phosphorylation of 




Name: LaSharon D. Mosley 
Work Address: 
James Graham Brown Cancer Center 
580 S. Preston Street, Baxter II Room 311 
Louisville, KY 40202 
(502) 852-2881 
Education: 
University of Louisville, Louisville, KY 
Ph.D., Pharmacology & Toxicology 
Graduation date: November 2009 
Dissertation Title: Mechanisms Mediated by CXCL 12 Signaling through CXCR4 
and CXCR7 in Breast Cancer 
University of Louisville, Louisville, KY 
M.S., Pharmacology & Toxicology 
Graduation date: May 2007 
Thesis Title: Role of Estrogen Receptors Alpha and Beta in Thyroid Cancer 
Mississippi University for Women, Columbus, MS 
B.S., Chemistry & Biology 
Graduation date: January 2000 
Scientific/Professional Experience: 
2007-2009; PhD 
Department of Pharmacology & Toxicology, University of Louisville 
Research Focus: The Role of CXCR7 in Breast Cancer Cell Progression 
Dissertation Advisor. Dr. James W. Lillard, Jr. 
2004-2007; M.S. 
Department of Pharmacology & Toxicology, University of Louisville 
Research Focus: Role of estrogen receptors alpha and beta in normal and 
neoplastic thyroid cells 
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Thesis Advisor: Dr. Richard Goldstein 
2000-2003; Tissue Culture Core Director/Research Assistant 
Tulane University Center for Gene Therapy 
Research Focus: Isolation of adult stem cells from primary cultures to treat brittle 
bone and Parkinson's diseases 
Principal Investigators: Drs. Darwin Prockop and Donald Phinney 
2000; Research Assistant 
Department of Biochemistry, University of Mississippi 
Research Focus: Effects of vinca alkaloids in P-19 and MCF-7 cell lines 
Principal Investigators: Drs. Barbara Rogers and Sharon Lobert 
1998; Summer Internship 
Department of Pharmacology; Tulane University 
Research Focus: Effects of phytochemicals in breast cancer celiline(s) growth 
and progression 
Principal Investigator: Dr. Nancy Hopkins 
Teaching Experience: 
2009 Judge, Nativity Academy Science Fair 
2005,2006 Judge, Newburg Middle School Science Fair 




Organic Chemistry Teacher Assistant, MUW 
General Chemistry Assistant, MUW 














Susan G. Komen Grants Committee Advisor (Local Affiliate) 
University of Louisville Graduate Student Travel Award 
FASEB/MARC Minority Student Travel Award (AAI) 
AACR Minority Scholar in Cancer Research Award 
FASEB/MARC Minority Student Travel Award 
Susan G. Komen Award (ICC meeting on inclusive policies) 
University of Louisville Graduate Student Travel Award 
Southern Regional Education Board Fellowship 
University of Louisville Minority Fellowship 
FASEB/MARC Minority Student Travel Award 
Surgery Oncology Graduate Fellowship, U of L 
IPIBS Fellowship, University of Louisville 





Most Outstanding Presentation in Biochemistry, Cellular & 
Molecular Biology, Mississippi Academy of Science 
Young Woman of the Year Award, Kemper County 













American Society for Pharmacology & Experimental 
Women in Cancer Research 
Minority in Cancer Research 
American Association for Cancer Research (AACR) 
American Association of Immunologists (AAI) 
BBGSO (Treasurer)- U of L 
American Chemical Society 
ISSCR (International Society for Stem Cell Research) 
Mississippi Academy of Science 
Beta Beta Beta Honor Society (MUW) 












Nativity Academy (mentor) 
Susan G. Komen Breast Cancer Foundation (volunteer) 
Food Drive for the Poor (Canaan Christian Church) 
American Cancer Society Relay for Life (BBGSO) 
Goodwill Donation Drive 
United Way Hurricane Katrina Fund Drive 
Habitat for Humanity (Tulane) 
Learn to Read Summer Program (Kemper County) 
Habitat for Humanity (MUW) 
Feed and Clothe the Poor Drive (MUW) 
Seminars and Presentations: 
2009 Posters Presentation, American Association of Immunology 
2009 Posters Presentation, American Assoc for Cancer Research 
2008 Poster Presentation, American Assoc for Cancer Research 
2008 Poster Presentation, American Association of Immunology 
2008 Susan G. Komen, Louisville Affiliate (Minority Inclusion) 
2007 Research Seminar, University of Louisville (Pharm & Tox) 
2006 Research Seminar, University of Louisville (Pharm & Tox) 
2005 Research Seminar, University of Louisville (Pharm & Tox) 
2002 Research Tulane Seminar, Tulane Center for Gene Therapy 
2001 Oral Presentation, Mississippi Academy of Science (2nd) 




















American Association of Immunologists 
American Association for Cancer Research 
SREB Faculty Compact 
Intercultural Cancer Council Meeting (local Susan G. 
Komen Affiliate) 
FASEB/AACR Meeting 
Experimental Biology Conference 
James Graham Brown Cancer Center Retreat 
SREB Faculty Compact 
AAI Conference 
Research Louisville 




Mississippi Academy of Science 
Mississippi Academy of Science 
1. Mosley L, Sharma P, Singh R, Singh S, Lillard JW Jr. "CXCL 11 and 
CXCL 12 mediate matrix metalloproteinase expression by breast cancer cells 
through CXCRT. 2009 AAI Meeting 
2. Mosley L, Singh R, Sharma P, Singh S, Lillard JW Jr. "CXCL 11 and 
CXCL 12 activates ERK1/2 and NF-KB in breast cancer cells via CXCR3, 
CXCR4, and CXCRT. 2009 AAI Meeting 
3. Mosley L, Sharma P, Singh R, Singh S, Lillard JW Jr. "CXCL 11 and 
CXCL 12 Modulates Matrix Metalloproteinase Expression by Breast Cancer 
Cells predominately through CXCR7 Interactions". 2009 AACR Meeting 
4. Mosley L, Sharma P, Singh R, Singh S, Lillard JW Jr. "CXCL 11 and 
CXCL 12 Modulates ERK1/2 and NF-KB activation in Breast Cancer Cells via 
CXCR3, CXCR4, and CXCR7". 2009 AACR Meeting 
5. Mosley L, Sharma P, Singh R, Singh S, Lillard JW Jr. "Differential ~-3 
integrin of CXCR3, CXCR4, and CXCR7 Clustering on Breast Cancer Cells in 
Response to CXCL 11, CXCL 12, and Adrenomedullin". 2008 FASEB Meeting 
6. Mosley L, Sharma P, Singh R, Singh S, Lillard JW Jr. "CXCR7 and 
CXCR3 interactions promote breast cancer cell migration, adhesion, and 
survival." 2008 Annual American Association for Cancer Research Meeting, 
San Diego. 
7. Kumar A, Mosley L, Klinge C, Goldstein R. "Estradiol and Selective 
Estrogen Receptor Modulators (SERMs) modulate the proliferation of Thyroid 
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Cancer Cells: Role of Estrogen Receptors Alpha and Beta". 2007 Annual 
Endocrine Society Conference 
8. Goldstein RE, Klarer A, Mosley L, Agrawal A, Joshua J, Stein E, Zeiger 
M, Kebebew E, Waigel S, Beckers S, Zacharias Z, Ho S, Cheng RY. 
"Clustering of Papillary Thyroid Carcinomas from African-American and 
Caucasian Female Subjects into Distinctly Different Microarray Expression 
Profiles". The International Association of Endocrine Surgeons, Durban, 
South Africa, August 2005. 
9. Propst E, Mosley L, Rogers B, Lobert S. "Inhibition of Proliferation by 
Vinca Alkaloids in P-19 and MCF-7 Cell Lines". The Journal of the 
Mississippi Academy of Sciences. 2001 
10. Mosley L, Hopkins NE, Alworth WL. "The Effects of Phytochemical on 
MCF-7 Cell Growth and Estrogen Receptor Binding". The Journal of the 
Mississippi Academy of Sciences. 1999 
Manuscripts 
1. L. Mosley*, P. Sharma*, R, Singh, S. Singh, and J.W. Lillard, Jr. 2009. 
CXCL 12 activates matrix metalloproteinase expression and activation by breast 
cancer cells via CXCR4 and CXCR7 interactions. (in preparation) 
2. L. Mosley*, R, Singh*, P. Sharma, S. Singh, and J.W. Lillard, Jr. 2009. 
CXCL 12 mediates ERK1/2 and NF-kB activation in breast cancer cells in a 
CXCR4 and CXCR7 dependent fashion. (in preparation) 
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